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edge of the molecular mechanisms contributing to the multiple causes of cardiovascular
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to summarize what is currently known about the mechanisms whereby microRNAs maintain
cardiovascular homeostasis and to attempt to identify some key unresolved questions that
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Copyright ª 2014, Chongqing Medical University. Production and hosting by Elsevier B.V. All
rights reserved.ldren’s Hospital, Department of Cardiology, Boston MA, 02115, USA.
ch.harvard.edu (R.L. Neppl), dwang@enders.tch.harvard.edu (D.-Z. Wang).
f Chongqing Medical University.
014.06.003
ing Medical University. Production and hosting by Elsevier B.V. All rights reserved.
Roles of microRNAs in cardiovascular homeostasis and disease 19Introduction
Cardiovascular Disease (CVD) is the leading cause of
morbidity and mortality worldwide. Broadly defined, CVD
includes primary diseases of the heart (i.e. myocardial
infarction, valvular stenosis or insufficiency, congenital
cardiac defects, hypertrophic and dilated cardiomyopathy,
and pericarditis) as well as diseases of the circulatory sys-
tem (i.e. ischemia and atheroslcerosis, vascular stenosis,
pulmonary hypertension, subarachnoid and intracerebral
hemorrhage, and arterial aneurysm and dissection). Ac-
cording to disease classifications outlined in the Interna-
tional Statistical Classification of Diseases and Related
Health Problems by the World Health Organization, when
adjusted for age, CVD accounts for approximately 30% of all
deaths1,2 in the United States alone. Hypertension affects
w65 million Americans; it increases the risk of stroke,
coronary artery disease, congestive heart failure and mor-
tality, yet approximately 43% of those undergoing phar-
maceutical treatment fail to respond.3 In addition to the
human cost, spending on CVD between 2010 and 2030 is
projected to increase from $272.5 billion to $818.1 billion in
total direct medical costs.4 It is anticipated that elucidating
the molecular mechanisms underlying the etiology of CVD
will lead to improved therapeutic outcomes.
With the discovery of RNAi5e7 and a new class of small
RNA molecules that inhibit translation of mRNAs,8e10 siRNA
and microRNA (miRNA) directed RNAi have become both a
widely used technique, and an important biological pro-
cess. MiRNAs are short (w22 nt) RNA molecules known to be
involved in embryogenesis and development,11e13 physio-
logical homeostasis14,15 and the etiology of disease.16e18
With the recent discovery of miRNAs in blood,19e21 it is
anticipated that miRNAs may become supplemental prog-
nostic and/or diagnostic biomarkers of CVD.
In this review, we will identify 1) clinical correlations
between the progression of disease and the dysregulation
of microRNAs, and 2) the causal relations between miRNA
mediated RNAi and the observed pathology. As such, we
will not discuss the mechanisms of miRNA biogenesis, but
rather invite readers to some elegantly written reviews on
the topic (see Refs. 22e28). Instead, this review will focus
on the current state of our knowledge regarding individual
miRNAs and their molecular role in maintaining physiolog-
ical homeostasis in the cardiovascular system. Further, we
will discuss novel non-canonical functions and signaling of
miRNAs, as well as key unresolved questions that warrant
future study. Herein we will give high priority to clinical
studies identifying correlations between miRNA expression
and diagnosis/prognosis, as well as in vivo mechanistic
studies indentifying their molecular target(s). Finally, we
would like to sincerely apologize to our many outstanding
colleagues, whose work may have been inadvertently
overlooked or not thoroughly discussed due to space
constraints.
Myocardial infarction
Myocardial Infarction (MI) afflicts 7.6 million Americans
each year, increases their susceptibility of a subsequent MI,
and often precedes cardiac remodeling, cardiomyopathy,and in some cases congestive heart failure.3 An acute MI
(AMI) results from the sudden impairment or cessation of
blood flow through one of the coronary arteries when an
atherosclerotic plaque (see Atherosclerosis) becomes un-
stable and ruptures, leading to the rapid formation of
thrombosis. Clinically, ST-segment Elevation Myocardial
Infarction (STEMI) involves the full thickness of the
myocardial wall and may also be caused by pericarditis,
whereas Non-ST-segment Elevation Myocardial Infarction
(NSTEMI) does not involve the entire ventricular wall
thickness. In a 2048 patient cohort, the odds ratio of fa-
tality by day 28 was 2.23 for STEMI patients compared to
NSTEMI patients, whereas the adjusted 7-year mortality for
28-day survivors was higher in NSTEMI than in STEMI pa-
tients.29 Rapid diagnosis of AMI is a critical determinant for
therapeutic intervention and survival prognosis as the
duration of impairment or cessation of blood flow to the
working myocardium greatly influences the severity of
cellular damage from ischemia to apoptosis and necrosis. In
addition to the initial cellular damage, cardiac remodeling
occurs in the infarct region which can lead to cardiomy-
opathies and Heart Failure (HF) (see Cardiomyopathy and
heart failure).
MicroRNAs have recently been identified as potential
prognostic indicators of HF following AMI. MiR-208b
(Table 1) was found to be increased w1600-fold in the
plasma of AMI patients when compared with patients pre-
senting with atypical chest pain without AMI.30 Alterna-
tively miR-208a, which was undetectable in non-AMI
patients with atypical chest pain, was found to be readily
detectable inw90% of patients having been diagnosed with
AMI.31 However, other groups found that miR-208a and miR-
208b are expressed at very low levels in the human heart32
and in only w30% of AMI patients.33 Additionally, miR-499-
5p was detectable in all control patients, elevated in all AMI
patients and AMI animal models, and found to track cTnI in
blood.32,33 Perhaps more importantly, circulating miR-499-
5p levels were associated with 12-month mortality in
elderly NSTEMI subjects,34 indicating its potential use as a
prognostic indicator. However, it should be noted that
miRNA-208a is specifically expressed in the heart, whereas
miR-208b and miR-499-5p are also expressed in skeletal
muscle,35 thereby confounding the interpretation of circu-
lating miR-208b and miR-499-5p for cardiac diagnostic and
prognostic purposes.
Recent advances in diagnostic and therapeutic inter-
vention have reduced in hospital mortality rates of patients
with AMI, but have lead to increased mortality rates in pa-
tients who survive the initial AMI only to develop in-hospital
or post-discharge Heart Failure (HF).36,37 Data from a subset
ofw200 patients in the original Framingham cohort showed
a 14% incidence of HF 5-years post-MI.38 In a more recent
population-based cohort of 7733 patients, 71% of AMI sur-
vivors developed HF within 5 years, 64% of which were
diagnosed within their first year post-MI.37 While not all
patients surviving AMI go on to develop HF (see
Cardiomyopathy and heart failure), predicting those more
likely to develop HF may increase their long term prognostic
outcome and quality of life. Matsumoto et al39 demon-
strated that in Osaka Acute Coronary Insufficiency Study
(OACIS) patients surviving AMI, p53-responsive miRNAs -192,
-194, and -34a were significantly upregulated in sera of
Table 1 Validated targets of miRNAs implicated in the pathophysiology of cardiovascular disease. What is evident from this
table is that multiple gene targets are targeted by multiple miRNAs under a variety of pathological conditions.
miRNA Gene targets Pathophysiology Ref(s).
Let7 Nf2 INFR, Cancer 250
1 RhoA, Cdc42, Nelf-A/WHSC2,
Kcnj2, Gja1, Ppp2r5a, Vegfa
CH, ARR, ANG 81,82,106,151
10 MAP3K7, bTRC, Flt1 ATH, ANG 122,154
15 Vegfa ANG 149
16 Kdr ANG 155
20 Vegfa, Hif1a ANG 150
21 Pten, Pdcd4, Ppara, Mpv17l,
Sorbs2, Pdlim5
Cancer, ISC, INFR, CH 64,65,123,165,166,253
23 Xiap, MuRF1 CI, CH 95,261
25 Serca2, Ip3r1 ARR, HF 83
26 Kcnj2 ARR 90
29 Adamts7, Col1a1, Col1a2,
Col3a1, Fibrillin
ATH, ARR, CR 56,57,169
30 CTGF, MTP CR, ATH, DLD 54,182
33 CROT, CPT1a, HADHB, AMPKa,
IRS2, ABCA1, Npc1
ATH, DLD 179,180,183
34 Ppp1r10, vinculin, Sema4b,
Pofut1, Bcl6
MI, CH 52,53
93 Vegfa MetS 153
122 Slc7a1, Agpat1, Alpl, Cs,
Klf6, Prom1, Sox4
Cancer, DLD 185,186,217
125 Grin2a NSP 273
126 Spred1, Vcam1, Rgs16, Foxo3,
Bcl2, Irs1, Tsc1
ANG, ATH, INFR 130,133e135, 157,159
130 Pparg MetS 291
132 FoxO3, p300, p120RasGAP, MeCP2 CH, INFR, ANG,
Rett Syndrome
102,137e139
133 CTGF, RhoA, Cdc42, Nelf-A/WHSC2 CH, CR 54,106
143 Klf5, Ssh2, Mrtfb, Orp8 ATH, T2DM 128,302
144 ABCA1 DLD 181
145 Klf4, Klf5, Srgap1/2, Ssh2, Ace ATH 127e129
146 Tlr4, Myd88, Irak1, Traf6 INFR 251
155 Jarid2, Bcl6, eNOS, Socs1, c-MAF, Tnf CH, ATH, HT, INFR 96,99e101,160,211
181 Cyld, Gria2 Cancer, NSP 253,274
192 Sip1 CR 51
199 Dyrk1a CH 93
200 Vegfa Diabetic Retinopathy 152
204 Mafa T1DM 299
208 Med13 CH, MetS 67,68,287
206 Vegfa ANG 151
210 Gpd1l, Efna3, Ptp1b, Rad52,
E2f3, Casp8ap2, Iscu
HYP, cMet 230e236
212 FoxO3 CH 102
214 Slc8a1, Bcl2l11, Ppif CR 80
221/222 p27kip1 ATH 168
223 Icam1, Gria2, Grin2b, Pknox1 ATH, CI, MetS 176,275,290
296 Hgs ANG 156
301 Pias3 INFR 252
320 Aqp1, Aqp4, Hsp6b, Ets2, Mmp9,
Emilin2, Nrp1, Pfkm
CI, MI/ISC, Cancer,
ANG, cMet
265,266,268e270
328 Pim1, Cacna1c, Cacnb1, Igf1r Cancer, ARR, HYP 84,239,249
342 Akt1, Bmpr2 ATH 161
375 Cadm1, Gphn, Cav1, Id3, Smarca2,
Rasd1, Aifm1, Mtpn, Vti1a
T1DM 294,298
378 Med13, Crat DLD, MetS 286
380 Tp53 Cancer 78
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Table 1 (continued )
miRNA Gene targets Pathophysiology Ref(s).
424 Cul2 HYP, ANG 228
425 Nppa HT 222
484 Fis1 HYP, cMet 77
486 Pten, Foxo1a CH 158
499 Calcineurin, Drp1, Sox6, Purb, Sp3,
Hp-1b, Med13, Mstn, Mapk6
CH, Striated Muscle
Performance
35,73,74
637 ATP6VOA1 HT 218
Arrhythmia e ARR, Atherosclerosis e ATH, Angiogenesis e ANG, Cardiac Hypertrophy e CH, Cerebral Infarct e CI, Cardiac Remodeling e
CR, Cellular Metabolism e cMet, Dyslipidemia e DLD, Heart Failure e HF, Hypertension e HT, Hypoxia e HYP, Inflammation and Immune
Response e INFR, Ischemia e ISC, Metabolic Syndrome e MetS, Myocardial Infarction e MI, Neuronal and Synaptic Plasticity e NSP, Type
1 Diabetes e T1DM, Type 2 Diabetes e T2DM.
Roles of microRNAs in cardiovascular homeostasis and disease 21those who developed de-novo HFwithin 1 year. In a subset of
the OACIS cohort who died within a year of discharge due to
cardiac cause, sera expression of miR-155 and miR-380*
were found to be increasedw3e4-fold in the convalescent
stage when compared with those who returned for their 1
year follow-up.40 Though this would suggest the possibility
that miR-155 and miR-380* may be potential prognostic in-
dicators for HF, the causal roles these miRNAs play in the
progression of HF remain uncertain.Cardiomyopathy and heart failure
Cardiac remodeling is a complex biological process
involving deleterious perturbations in extracellular matrix
(ECM) deposition and composition, morphological and
phenotypic changes in the resident cardiac fibroblast pop-
ulation, and under extreme conditions, heart failure. While
there are numerous pathophysiological causes of the
various clinical subtypes of the cardiomyopathies, miRNAs
are now being identified as crucial mechanistic players in
the progression from normal to deleterious cardiac function
under multiple pathophysiological stimuli. For the purposes
of this review we will consider cardiomyopathy in general
rather than each specific subset and attempt to clarify the
newfound role of miRNAs in the progression of these
diseases.
Fibrotic extracellular remodeling of the cardiac ECM is a
deleterious consequence of ischemia, cardiac cell death
and ventricular pressure overload. Cardiomyocytes reside
in an ECM consisting of collagen fibrils that are composed
mainly of collagen type I (w80%) and type III (w10%), with
smaller contributions to the matrix coming from collagen
types IV, V, and VI, in addition to the matrix contributions
of laminin, elastin, glycosaminoglycans and others.41,42 In
clinical studies and in animal models of MI and cardiomy-
opathy, it has been well established that transient and
prolonged ischemia as well as left ventricular pressure
overload results in fibrotic scar formation in which resident
myofibroblasts secrete excessive extracellular matrix
components including collagens 1a1 (Col1a1), 1a2 (Col1a2),
3a1 (Col3a1) and matrix metalloproteinases which ulti-
mately lead to impaired left ventricular function.43e45
Similar ECM remodeling of the right ventricle occurs clini-
cally and in animal models of pulmonary hypertension,
chronic hypoxia, and AMI.46e49Cardiomyocyte specific postnatal deletion of Dicer
induced rapid death in juvenile and extensive cardiac
remodeling in adult mice,50 indicating the critical role of
miRNAs in maintaining cardiac homeostasis. Specifically,
miR-192 (Table 1) was found to inhibit Smad-interacting
protein 1 (SIP1), an E-box repressor similar to dEF1,
known to repress TGF-b dependent transcription of Col1a2
expression.51 In addition, Bernardo et al demonstrated
that inhibition of the miR-34 family, but not miR-34a
alone, attenuates morphological changes and patholog-
ical left ventricular remodeling in both pressure overload
and MI models.52 Mechanistically it was determined that
the miR-34 family targets vinculin, Sema4b, Pofut1 and
Bcl6. Inhibition of the miR-34 family resulted in significant
increases in post-TAC aMHC/bMHC and phospho-AKT/
total-AKT ratios as well as capillary density. Interest-
ingly, repression of miR-34a prevented both age-
associated and post-AMI cardiomyocyte apoptosis and
interstitial fibrosis by maintaining/increasing PNUTS
(PPP1R10) expression,53 suggesting that the miR-34 family
regulates signal transduction pathways necessary for
cellular adhesion and cytoskeletal rearrangements.
Further, miR-133b and miR-30c were found to repress
CTGF expression thereby reducing Col1a1 and Col3a1
levels,54 while miR-133a transgenic mice exhibited signif-
icantly reduced interstitial fibrosis and cardiomyocyte
apoptosis in a mouse model of pressure overload CVD,55
suggesting a role for miR-133 in repressing ECM remodel-
ing and cardiomyocyte loss. Further, inhibition of miR-29b
alone was sufficient to significantly increase Col1a1,
Col1a2, and Col3a1 expression in vivo.56,57 In addition to
miR-29, miR-21 expression was found to be increased >2-
fold in intermediate and late-stage heart failure in mice.58
Mechanistically, it has been suggested that miR-21 con-
tributes to the extent of interstitial fibrosis and progres-
sive heart failure and by selectively promoting fibroblast
survival through targeting of i) Spry1 and thereby aug-
menting ERK-MAP kinase activity,58,59 ii) PDCD4 thereby
inhibiting apoptosis,59,60 iii) PTEN thereby enhancing Akt
signaling61e63 and iv) PPARa thereby altering lipid meta-
bolism.64 Interestingly, myofibroblast derived exosomes,
enriched in miR-21*, were found to induce cardiomyocyte
hypertrophy by targeting SORBS2 and PDLIM5.65 However,
genetic ablation of miR-21 fails to inhibit cardiac hyper-
trophy and pathological cardiac remodeling in multiple
models of CVD,66 suggesting that the concerted signaling
22 R.L. Neppl, D.-Z. Wangof miR-21, miR-21*, and other miRNAs are necessary for
pathological remodeling within the heart.
We, and others, first demonstrated the causative role of
miR-208a in the pathological remodeling of the heart in a
mouse model of pressure overload cardiac hypertro-
phy.67,68 Mechanistically, it was demonstrated that miR-
208a represses THRAP1/MED13 to inhibit T3 signaling,
thereby increasing bHMC and miR-208b expression, as well
as other fetal genes characteristic of cardiac remodeling.
Of therapeutic interest, inhibition of miR-208a led to a
dose dependent prevention of bHMC and ECM remodeling
while simultaneously improving cardiac function in a rat
model of hypertension (see Hypertension) induced heart
failure.69 Further, T3 signaling induces miR-208a-
dependent cardiac expression of miR-499 to control skel-
etal muscle fiber type by targeting Sox6.35 MiR-499 was
found to be increased in cardiac Gaq transgenic mice,70
which stimulates cardiomyocyte hypertrophy, apoptosis,
and heart failure in vivo.71,72 Previously demonstrated to
target Med13/Thrap1, myostatin (Mstn), Mapk6, and Sp3,73
cardiomyocyte specific ectopic expression of miR-499 in
mice lead to progressive cardiac enlargement, contractile
dysfunction, and overt dilated cardiomyopathy by 20 weeks
of age,70 thus indicating a causal relation between dele-
terious miR-499 expression and heart failure. Paradoxi-
cally, miR-499 transgenic mice w8e10 weeks of age were
found to be resistant to left ventricular remodeling after
ischemiaereperfusion injury through repression of calci-
neurin and Drp1,74 proteins which play key roles in hyper-
trophic signaling, and mitochondrial fission and energetics.
However, these disparate observations may be reconciled
by the ages of the mice in question. Given these observa-
tions, it seems likely that miR-499 plays a short-term pro-
tective role under ischemiaereperfusion injury by
regulating Drp1 levels, and thus mitochondrial energy
production, whereas long-term expression of miR-499 is
deleterious by promoting hypertrophic signaling through its
repression of myostatin.
A metabolic shift from fatty acids in the healthy
myocardium to that of increased glucose metabolism is
known to accompany heart failure.75,76 Interestingly, miR-
484 was found to target Fis1 thereby preventing mito-
chondrial fission and apoptosis in anoxic cardiomyocytes,77
whereas miR-380-5p was found to directly target P53,
thereby inhibiting apoptosis.78 In dilated cardiomyopathy
(DCM) patients, and in a mouse model of DCM, the
expression of Dnm3os encoded miRs-199a and -214 were
found to be dramatically increased.79 Interestingly, it was
observed that inhibition of both miR-199a and miR-214, but
not individual inhibition, attenuated both pathological
remodeling and the metabolic switch from fatty acids to
glucose by preserving the expression of PPARd. MiR-214∕
mice in which miR-199a expression is preserved, exhibited
decreased survival following MI and intensified ische-
miaereperfusion induced cardiomyocyte apoptosis and ECM
remodeling.80 Mechanistically, it was determined that miR-
214 directly targets multiple genes involved in metabolism
and apoptosis including the sodium/calcium exchanger
Ncx1 (Slc8a1), pro-apoptotic Bcl2 family member Bcl2-like
11 (Bcl2l11), and Ppif (cyclophillin D), a mediator of Ca2þ
and oxidative damage-induced cell death independent of
the Bcl2 pathway.Interestingly, miR-208∕ mice demonstrate a marked
absence of P-waves on ECGs,68 indicating a potential role of
miR-208 in controlling atrial depolarization. MiR-1 expres-
sion was found to be significantly increased in humans with
coronary artery disease as compared with those without
coronary artery disease, and to precede Phase II arrhythmia
following AMI in a rat model.81 Repression of miR-1 was
found to inhibit arrhythmogenesis in the ischemic heart by
derepressing connexin-43 (Gja1) and Kþ channel subunit
Kir2.1 (Kcnj2) expression.81 Further, the arrhythmogenic
activity of miR-1 was found to be through selective
repression of the protein phosphatase PP2A regulatory
subunit B56a, thereby resulting in enhanced RyR2 phos-
phorylation at S2814, elevated diastolic SR Ca2þ leak, and
arrhythmogenic myocyte Ca2þ cycling.82 Interestingly,
in vivo inhibition of miR-25 was found to sustain the
expression of Serca2a and IP3R1,83 thereby maintaining
normal Ca2þ dynamics during excitationecontraction
coupling and halting the progression of heart failure. MiR-
328 expression was found to be increased >2-fold in atrial
samples from atrial fibrillation (AF) patients, and demon-
strated to repress atrial expression of the cardiac L-type
Ca2þ channel a1c and b1 subunits,84 thereby contributing to
further atrial remodeling and the characteristic defects in
L-type Ca2þ current densities associated with AF.85e88
Expression of miR-26a and miR-26b is reduced in a mouse
model of pressure overload hypertrophy89 and in human AF
patients.90 Interestingly, miR-26a/b were found to be
transcriptional targets of NFAT and to directly repress
Kir2.1/KCNJ2 protein levels and IK1 density,
90 indicating a
mechanistic role of reduced miR-26a/b expression in car-
diac hypertrophy and the progression of AF. Collectively,
these studies indicate that miRNAs are key regulators of
physiologically relevant ion currents necessary for cellular
homeostasis, excitationecontraction coupling, and cardiac
function.
NFAT transcription factors, both necessary and sufficient
to mediate cardiac hypertrophy, are antagonized by a va-
riety of kinases including GSK3b, p38 and JNK thereby
inhibiting their nuclear accumulation and diminishing hy-
pertrophic gene expression. Calcineurin (Ppp3ca) is a
calcium/calmodulin-dependent serine/threonine protein
phosphatase that dephosphorylates NFAT thereby initiating
hypertrophic gene expression.91,92 Recent evidence sug-
gests that miRNAs play both synergistic and antagonistic
roles in calcineurin/NFAT signaling. MiR-199b was identified
as a direct transcriptional target of calcineurin/NFAT to
repress the NFAT inhibitory nuclear kinase Dyrk1a in a feed
forward mechanism to enhance calcineruin-dependent
gene expression.93 Increased calcineurin/NFAT signaling in
conjunction with decreased miR-25 signaling converged to
deleteriously re-express Hand2 in order to initiate cardiac
remodeling.94 In addition, miR-23a has been shown to be
necessary for the induction of hypertrophy in vivo by
directly inhibiting MuRF1 in response to calcineurin/NFATc3
signaling.95 Mir-155 has also been demonstrated to play a
critical role in the pathological hypertrophic response as
genetic ablation of miR-155 was shown to inhibit car-
diomyocyte hypertrophy and dramatically increase the long
term survival of calcineurin transgenic mice,96 suggesting
that miR-155 targets genes involved in anti-hypertrophic
signaling. Mechanistically, it was found that miR-155
Roles of microRNAs in cardiovascular homeostasis and disease 23directly inhibits the expression of Jarid2, a known regulator
of PRC2 activity,97,98 suggesting that miR-155 plays a role in
regulating epigenetic gene silencing. Interestingly, trans-
plantation of bone marrow from miR-155∕ to WT mice
was sufficient to inhibit hypertension induced car-
diomyocyte hypertrophic growth and the concomitant
deleterious loss of cardiac function by maintaining macro-
phage expression of suppressor of cytokine signaling 1
(SOCS1).99 This is consistent with prior reports indicating a
crucial role of miR-155 in regulating immune responses and
cytokine signaling by targeting c-Maf100 and TNF.101
Collectively, these results demonstrate the necessity of
miR-155-dependent paracrine signaling from bone marrow-
derived cells in pathological cardiac remodeling and
hypertrophy.
Further, elevated expression of miR-212 and miR-132
(the miR-212/132 family is separated by less than 500 nt
within the genome) is necessary and sufficient contributors
to pathological cardiac hypertrophy by targeting FoxO3
expression102; acting largely to activate the expression of
Atrogin-1 (Fbxo32), an E3-ubiquitin ligase that initiates the
degradation of calcineurin in cardiomyocytes.103,104 Poly-
cistronic miR-1 and miR-133, first identified as factors
necessary for normal skeletal muscle myogenesis,105 were
found to be dramatically downregulated in mouse model of
pressure overload cardiac hypertrophy.106 Adeno-
associated viral 9 (AAV9) cardiac delivery of miR-1
improved cardiac function in a rat model of pressure
overload CVD,107 while overexpression of miR-1 or miR-133,
and in vivo inhibition of miR-133, reduced and enhanced,
respectively, the severity of pressure overload cardiac hy-
pertrophy by maintaining the normal physiological levels of
RhoA, Cdc42 and Nelf-A/WHSC2.106 RhoA and Cdc42 are
known to be associated with cytoskeletal and myofibrillar
rearrangements,108,109 key hallmarks of cardiomyocyte hy-
pertrophy. Collectively, these data indicate the myriad
signaling and biological processes by which miRNAs regulate
cardiac function, homeostasis, and the progression of car-
diac remodeling and hypertrophy.Atherosclerosis
Atherosclerosis, characterized by a progressive narrowing
of the lumen of blood vessels, is a complex disease
involving vascular endothelial cells, vascular smooth muscle
cells, macrophages and their monocyte progenitors, neu-
trophils, and others,110,111 and a primary risk factor for
Myocardial Infarction (see Myocardial infarction) and stroke
(see Subarachoid and intercerebral haemorrhage and
infarction).1,3 One of the primary factors in the etiology
of atherosclerosis is the accumulation of oxidized phos-
pholipids in atherogenic regions of the arterial tree with
subsequent infiltration by inflammatory cells and activated
endothelial cells, forming a fibrous plaque.112e114 As the
plaque expands, inducing neointimal formation and
vascular remodeling, the luminal cross-sectional area de-
creases resulting in a progressive loss of volumetric blood
flow and the onset of ischemia.
Previously thought of as a lipid storage disease, athero-
protective and athero-genic endothelial inflammatory
signaling has emerged as a critical mechanistic focalpoint in the etiology of atherosclerosis.115,116 Pro-
inflammatory effector molecules potentiate plaque for-
mation and many of the immune cells enriched in the
nascent plaque are activated, actively producing inflam-
matory cytokines.117e120 Nascent atherosclerotic plaque
formation was found to be significantly attenuated in
Vcam-1∕ mice,121 indicating a critical role of this adhe-
sion molecule in the etiology of atherosclerosis. In primary
human endothelial cells, miR-10a (Table 1) was found to
inhibit Vcam-1 expression by directly targeting MAP3K7 and
bTRC,122 upstream activators of NF-KB signaling known to
induce Vcam-1 expression. More interestingly, miR-10a was
found to be expressed at significantly lower levels in the
atherosclerosis prone aortic arch (as compared with the
descending thoracic aorta) and the caudal and cranial walls
of the renal artery (adjacent to the descending abdominal
aorta, as compared with the distal renal artery). Though,
this would suggest a causal relationship between miR-10a
expression and Vcam-1 dependent atherogenic signaling,
further in vivo studies are needed.
Non-laminar/low-sheer chaotic flow, such as occurs at
atherosclerosis prone bifurcations and curves within the
vascular tree, has been shown to act in a positive feedback
mechanism to induce and maintain the expression of miR-
21 and the endothelial pro-inflammatory/pro-atherogenic
genes Vcam-1 and Mcp-1. Mechanistically, it was deter-
mined that miR-21 directly targets PPARa, which is an in-
hibitor of AP-1 dependent Vcam-1, Mcp-1, and miR-21
expression.123 However, atheroprotective pulsatile
laminar flow, such as occurs during straight vascular seg-
ments, has been shown to increase KLF2124 and the miR-23b
cluster (miR-23b and miR-27b)125 to maintain endothelial
homeostasis. Interestingly, atheroprotective flow actively
maintains endothelial homeostasis, by increasing KLF2
expression in part by suppressing the expression of miR-
92a,124 while simultaneously increasing the expression of
miR-23b in order to repress E2F1 expression and Rb phos-
phorylation,125 thus maintaining endothelial quiescence
and physiological homeostasis. In addition, endothelial
KLF2 induces miR-143/145 expression, which is then
transported by non-apoptotic microvesicles to smooth
muscle cells (SMCs) to promote an atheroprotective
phenotype.126 Consistent with this observation, miR-143/
145 null mice are hypotensive, exhibit profound thinning
of the tunica media in large conduit vessels, and have a
decreased ratio of quiescent contractile to synthetic
SMCs.127,128 Interestingly, miR-143 and miR-145 are neces-
sary for the acquisition and maintenance of the quiescent
contractile SMC phenotype by targeting Ace,127 whereas
loss of miR-143, miR-145, or both, significantly reduces
neointimal formation following carotid artery ligation128,129
through repression of multiple genes involved in SMC
migration and hypertrophic growth. Collectively these data
indicate that precise temporal control of miRs-143/145
expression is a primary determinant in neointimal forma-
tion, and suggest that transient inhibition of miR-143 and/
or miR-145 in the region of vascular injury (i.e. vascular
stent or balloon angiography) would provide therapeutic
benefit.
Alternatively, endothelial derived apoptotic (vesicular)
bodies (AB) enriched in miR-126 are found to deliver their
miRNA-cargo to recipient cells in order to repress SPRED1
24 R.L. Neppl, D.-Z. Wangand RGS16, thereby leading to the increased secretion of
the pro-angiogenic chemokine CXCL12 in Apoe∕ mice.
Repetitive injections of miR-126 containing ABs significantly
reduced carotid artery atherosclerotic plaque area, as well
as its macrophage and SMC content, by increasing the
number of circulating Sca1þ lineage progenitors.130
Plasma levels of CXCL12 and its receptor CXCR4 were
significantly decreased in patients with unstable angina, as
compared with patients with angina pectoris,131 whereas
CXCR4þ bone marrow-derived mononuclear cells (BMCs)
were found to be enriched in pro-angiogenic cytokines HGF
and PDGF-BB, improving neovascularization in a mouse hind
limb ischemia model.132 Additionally, miR-126 is necessary
for normal angiogenesis and vascular integrity in both the
mouse and zebrafish model systems.133,134 Though an in-
tegral component of normal vascular development, miR-
126 null mice show inhibited neointimal formation
through decreased SMC proliferation and apoptosis in a
carotid artery ligation model,135 suggesting that miR-126
and other pro-angiogenic miRNAs may be of therapeutic
interest.
Interestingly, post-AMI transplantation of saphenous
vein-derived pericyte progenitor cells (SVPs) resulted in
dramatic improvement of myocardial blood flow and neo-
vascularization through the secretion of VEGFA,
angiopoietin-1, angiogenic cytokines, and miR-132,136
thereby enhancing paracrine signaling to further induce
angiogenic and survival responses within the myocardium.
Mir-132 is known to target MeCP2,137 p300,138 and the anti-
angiogenic Ras inhibitor p120RasGAP.139,140 While
angiopoietins-1 and -2 are both ligands for the receptor
tyrosine kinase TIE2,141 angiopoietin-2, sensitizes endo-
thelial cells to TNFa induced expression of pro-
inflammatory adhesion molecules Icam-1 and Vcam-1,142
and antagonizes the pro-angiogenic signaling of angiopoie-
tin-1.141,143 VEGFA was originally identified as a heparin-
binding protein present in serum-free tumor cell culture
medium that induced normal guinea pig skin microvascu-
lature to become hyperpermeable, and referred to as
vascular permeability factor (VPF).144,145 Interestingly,
VEGFA/VPF is also a potent pro-inflammatory cytokine.
VEGF165 transgenic mice have an asthma-like phenotype
characterized by mucus metaplasia, smooth muscle hy-
perplasia, vascular remodeling, inflammation, edema and
angiogenesis.146 Further, reduction in VEGFA levels (VEGF
TrapR1R2) significantly reduced inflammatory cell recruit-
ment in vivo in a mouse model of corneal neo-
vascularization,147 while angiopoietin-1 can repress the
VEGFA induced increase in Vcam-1 and Icam-1 mRNA
expression and leukocyte adhesion in HUVECs.148 Pro-
angiogenic VEGF signaling is necessary to induce the
quiescent to proliferative phenotypic switch necessary for
both the repair the vascular endothelium following injury,
and for angiogenesis and neovascularization. VEGFA is
known to be directly targeted by multiple miRNAs including
miR-15a,149 miR-20b,150 miR-1 and miR-206,151 miR-200b,152
and miR-93.153 In addition, intracellular VEGF signaling is
similarly regulated by multiple miRNAs, including miR-10
targeting of the VEGF receptor Flt1,154 miR-16 and miR-
424 targeting of the VEGF receptor Kdr,155 miR-296 medi-
ated repression of PDGF receptor-b and Kdr through direct
targeting of Hgs,156 miR-126 targeting of the Ras inhibitorSpred1,133,134,157 miR-486 targeting of the PI3K/Akt in-
hibitors PTEN and Foxo1a,158 and miR-126 targeting of the
mTor inhibitor Tsc1.159 Collectively, these studies indicate
that miRNA-dependent regulation of VEGFA/angiopoietin
signaling plays a crucial role in maintaining the delicate
balance between pro/anti-angiogenic and pro/anti-
inflammatory signaling within the endothelium.
In ApoE deficient mice, leukocyte-specific loss of miR-
155 was sufficient to reduce plaque size and the number of
plaque associated macrophages after partial carotid liga-
tion. In addition, miR-155 null macrophages stimulated with
oxidized phospholipids expressed markedly lower levels of
the monocyte recruiting chemokine CCL2. Mechanistically,
miR-155 was found to directly target the NF-kB inhibitor
Bcl6.160 Interestingly, miR-342-5p may be an upstream
activator of miR-155-dependent inflammatory signaling, as
its inhibition increased Akt1, Bmpr2 and anti-inflammatory
signaling while repressing miR-155 expression and athero-
sclerotic plaque formation.161 Further, inhibition of miR-
342-5p reduced the number of macrophages and smooth
muscle cells in neointimas. Together these data indicate
causal roles for miR-155 and miR-342-5p in progression of
vascular inflammation, neointima formation and athero-
sclerosis. In addition, TLR4 (an upstream regulator of miR-
146a/b, miR-132, and miR-155162) has been found to be
preferentially expressed by macrophages enriched in
atherosclerotic plaques.163 Interestingly, miR-21 was shown
to be necessary to inhibit pro-inflammatory PDCD4-
dependent TLR4 signaling and NF-kB activation, thus
negating the toxic effects of repressed anti-inflammatory
signaling in response to lipopolysaccaride .164 MiR-21 has
been previously shown to repress PDCD4 expression in
cancer cells,165,166 resulting in increased tumor cell prolif-
eration, invasion and metastasis. In addition, elevated miR-
21 expression is observed in carotid artery neointimal le-
sions following balloon angioplasty, whereas inhibition of
miR-21 dramatically reduces neointimal formation.167
Together these results strongly suggest a critical role of
miR-21 in atherogenic inflammatory signaling, which may
be due, in part, to is pro-proliferative effects regardless of
cell type. Expression of miR-221/222 was found to be
significantly and transiently increased following balloon-
injury in adult male rats. Consistent with its pro-
proliferative effects by repressing p27Kip1, inhibition of
miR-221 significantly represses neointimal formation
following balloon injury.168 Further, miR-29 was shown to
play a crucial role in repressing ADAMTS-7 ,169 previously
identified in GWAS of patients with coronary artery dis-
ease170 and coronary artery calcification.171 Silencing of
ADAMTS-7 in vivo substantially inhibited neointimal for-
mation and SMC migration in response to pro-inflammatory
cytokines,172 thus implicating miRNAs as multifactorial
mediators of vascular inflammation, atherosclerotic plaque
formation and subsequent ECM remodeling and neointima
formation.
While the causal relation between lipid accumulation
and atherosclerosis has been well documented for years,
the cellular and molecular causes of lipid accumulation and
subsequent atheroslcerosis in atheroprone regions of the
vasculature are becoming increasingly clear. Increasing the
circulating levels of HDL were found to induce regression of
atherosclerosis in ApoE deficient mice 173 and in humans ,174
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HDL levels. Interestingly, the anti-atherosclerotic effects of
HDL may be due, in part, to HDL-delivered miRNAs whose
expression signature changes under disease conditions.175
Endothelial Icam-1 was found to be directly targeted by
HDL-delivered, rather than endothelial transcribed, miR-
223 in order to repress inflammatory gene expression,176
indicating heterocellular communication through HDL-
delivered miRNAs in vivo. Northern blot analysis indicates
that miR-223 is highly expressed in bone marrow, lung, and
spleen with detectable expression in liver and thymus,177
suggesting that the liver is the likely source of HDL-
delivered miR-223 to the vascular endothelium. Interest-
ingly, 4 weeks after inhibition of miR-33, LDL receptor null
mice were found to have significant reductions in previously
established atherosclerotic plaques and elevated circu-
lating HDL levels,178 through direct targeting of the aden-
osine triphosphate-binding cassette transporter 1 (ABCA1)
and the endolysosomal transport protein NPC1.179 Further,
inhibition of miR-33a and miR-33b increased hepatic
expression of cholesterol transporter ABCA1 leading to
increased circulating HDL levels and a marked repression of
VLDL associated triglycerides in non-human primates.180
MiR-144 is found to be upregulated in conditions of hyper-
lipidemia and hypercholesterolemia by LXR signaling in the
liver, and to directly repress ABCA1 expression,181 while
miR-30c directly represses MTP expression with corre-
sponding reductions in APOB secretion, total cholesterol
and triglycerids, and atherosclerotic plaques.182 MiR-33a is
also known to directly target CROT, CPT1a, HADHB, AMPKa
and IRS2,183 key regulators of cholesterol homeostasis,
fatty acid metabolism and insulin signaling. Finally, inhibi-
tion of miR-122 was found to significantly reduce total
serum cholesterol and liver steatosis in mice fed a high-fat
diet for 19 weeks,184 thus indicating potential therapeutic
benefits of miR-122 inhibition in patients with dyslipidemia.
Mechanistically, miR-122 was found to target Agpat1,185 an
enzyme critical for triglyceride synthesis, and multiple
genes (see Table 1) involved in hepatic differentiation,
fibrosis, and homeostasis.186 Together these data implicate
multiple miRNAs as key regulators of circulating HDL levels,
thereby modulating circulating LDLs, triglycerides and
other lipids involved in the pro-atherosclerotic vascular
inflammatory response.Hypertension
Essential hypertension effects w65 million Americans,3
however, the prevalence and hospitalization rates of HF
patients with prediagnosed hypertension has continued to
increase. In addition, the rates of end-stage renal disease
(ESRD) have been increasing yearly since the early 1990s,
with hypertension second only to diabetes as its primary
precursor.187 Although the precise pathogenesis of essential
hypertension remains elusive, it has been suggested that
defective sodium handling and regulation of fluid volumes
by the kidney are a primary cause.188 Further, virtually all
the known Mendelian disorders impacting blood pressure
are caused by dysregulation of salt and water reabsorption
in the distal nephron.189 Alternatively, other studies have
identified primary vascular defects impacting peripheralresistance without direct involvement of the renin-
angiotensis-system (RAS).190e194 Current oral antihyper-
tensive treatment options include diuretics, beta-blockers,
aldosterone receptor blockers, angiotensin-converting
enzyme inhibitors, calcium channel blockers, a1 blockers
and direct vasodilators.187 Given their effectiveness, ACE
inhibitors and Angiotensin receptor blockers, remain a
mainstay in the treatment of diabetes, heart failure,
atherosclerosis and hypertension.195
Terminal pulmonary arterial hypertension (PAH) is
characterized by lesions composed of hyperproliferative PA
endothelial cells and smooth muscle cells.196,197 Although
the intrinsic cellular and molecular mechanisms contrib-
uting to EC and VSM proliferation and phenotypic switching
have been studied for years,110,198e201 recent evidence
strongly suggests that crosstalk between these two cellular
populations is dramatically altered, thereby inducing per-
turbations in molecular signaling and contributing to the
loss of vascular homeostasis.197,202e204 Of particular inter-
est in PAH, Apelin (APLN) is known to be highly expressed in
the endothelium of the pulmonary and systemic vascula-
ture,205 and to decrease blood pressure in both normal and
hypertensive mice206 likely through activation of eNOS.207
Recently, perturbations in the apelin (APLN) e apelin re-
ceptor (APLNR, also referred to as APJ or AGTRL1) signaling
axis have been observed in PA hypertensive patients.208,209
Mechanistically, it was reported that impaired APLN
signaling leads to increased FGF2, FGFR1, PASMC prolifer-
ation and vascular tone by a reduction in APLN-mediated
expression of miR-424 and miR-503.210 In addition, miR-
155 (Table 1) was found to repress eNOS expression, and
endothelium dependent vasorelaxation, in a TNFa model of
endothelial dysfunction.211
Angiotensin II regulates a variety of non-hemodynamic
physiological processes including fluid homeostasis, renal
function, aldosterone production, induction of reactive
oxygen species, apoptosis and hypertrophy, in addition to
its role as a vasoconstrictor. Crowley et al212 demonstrated
that renal angiotensin type-1 receptors (AT1R) are required
for the development of Ang II-dependent hypertension and
cardiac hypertrophy. Interestingly, a high correlation has
been identified in hypertensive patients between Ang II
sensitivity and the presence of the þ1166A/C single
nucleotide polymorphism (SNP) in the AT1R gene.
213 The
presence of the þ1166A/C SNP has been associated with
increased Ang II-dependent vasoconstriction in isolated
human arteries.214 Although consistent with in silico ana-
lyses suggesting that the þ1166A/C SNP would inhibit miR-
155 mediated repression of AT1R, this has yet to be vali-
dated in vivo. Additionally, decreased expression of the
cationic amino acid transporter encoded by Slc7a1 in hy-
pertensive patients is associated with a þ2157C/T SNP
located within its 30UTR.215 The cationic amino acid trans-
porter encoded by Slc7a1 (CAT-1) is the principal arginine
transporter in endothelial cells; physiologically, arginine is
an essential metabolite in the production of the potent
vasodilator nitric oxide. Interestingly, an inverse relation
between miR-122 and CAT-1 protein expression is observed
in the developing liver, with miR-122 expression increasing
dramatically from ED12.5 to P21.216 In addition, miR-122
has been shown to directly inhibit translation of Slc7a1 in
a hepatocarcinoma cell line.217 However, the mechanism
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expression levels remains to be determined. A 30UTR poly-
morphism at Tþ3246C (rs938671) in the vacuolar Hþ-ATPase
subunit ATP6VOA1 is found to create a miR-637 binding
motif, thereby inducing changes in vacuolar pH and secre-
tory protein processing of Chromogranin A (CHGA) into
Catestatin.218 CHGA is the precursor to several bioactive
peptides including catecholamine release-inhibitory Cate-
statin (human CHGA352e372), the vasoconstrictor inhibitors
Vasostatin I (human CHGA1e76) and Vasostatin II (human
CHGA1e115),
219,220 and is linked to familial hypertension
along with ATP6VOA1.221 Patients with the rs5068 SNP (AG
vs. AA, located in the 30UTR) of the NPPA gene, were found
to have significantly higher blood pressure, and up to 50%
higher ANP levels in AG individuals than in AA individuals.222
Mechanistically it was determined that the AG allele
inhibited the ability of miR-425 to repress plasma ANP
levels. Using a bioinformatics approach, Nossent
et al identified SNPs associated with hypertension in the
30UTR of the arginine vasopressin 1A receptor (AVPR1A,
rs11174811), and hypotension in the 30UTRs of bradykinin 2
receptor (BDKRB2, rs5225 and rs2069591), and the throm-
boxane A2 receptor (TBXA2R, rs13306046).223 Thromboxane
A2 is an important platelet derived224 modulator of vascular
tone in the pulmonary arterial225 and cerebral arterial226
vasculature (see Subarachnoid and intercerebral
haemorrhage and infarction). Together, this data strongly
suggests that many of the genetic variations associated
with hypertension may be due to deleterious gain-of-
function and loss-of-function mutations to enhance or
repress miRNA-directed post-transcriptional gene expres-
sion (Fig. 1).
Chronic hypoxia is the most common cause of pulmonary
hypertension. Hypoxic conditions induce transcriptional
activation of multiple genes involved in angiogenesis and
metabolic adaptation. The central mediator in this
signaling cascade is the hypoxia-inducible factor (HIF-1),
which is composed of HIF-1a and HIF-1b subunits. Cytosolic
HIF-1a is maintained at low levels under normoxia by pro-
teasomal degradation following prolyl-hydroxylation.227
Interestingly, miR-424, previously identified as a down-
stream contributor of APLN signaling,210 was demonstrated
to target the ubiquitin ligase scaffold Cul2, thereby stabi-
lizing HIF-1a isoforms,228 and thus contributing to a feed-
forward signaling pathway to potentiate HIF-1 dependent
gene expression. However, this data also suggests that
many of the phenotypic observations associated with miR-Figure 1 Schematic representation of the effect of SNPs on
miRNA target sites. SNPs in the 30UTR of protein coding genes
may result in the loss or gain of a miRNA response element
(MRE), thereby deleteriously altering post-transcriptional gene
regulation.424 are due to its mechanistic effects on repressing E3-
ubiquitin ligase assembly and proteosome mediated pro-
teolysis. Alternatively, HIF-1 dependent miR-210 was found
to induce plieotropic effects in multiple cell lines.229 MiR-
210 was found to act in a positive feedback loop to pro-
mote HIF-1a stability and nuclear translocation by repres-
sing prolyl-hydroxylase activity by targeting GPD1L.230 In
addition, receptor tyrosine kinase ligand ephrin A3,231,232
homology-dependent DNA repair pathway member
RAD52,233 transcription factor E2f3,234 and caspase-8 asso-
ciated protein 2235 have all been examined as miR-210
targets in hypoxia.
Perhaps most interestingly, miR-210 was shown to
directly repress ISCU1/2, thereby reducing iron-sulfur
cluster formation and mitochondrial function via Complex
I and aconitase.236 In addition, HIF-1 signaling is known to i)
induce multiple genes involved in glucose transport and
glycolysis, ii) enhance the expression of enzymes respon-
sible for the shunting of pyruvate from the TCA cycle to
anaerobic metabolism, and iii) mediate a subunit switch in
cytochrome c oxidase thereby enhancing electron transport
chain (ETC) efficiency under hypoxic conditions.237,238 In-
hibition of ISCU1/2 expression and thereby TCA cycle
(aconitase) and ETC (Complex I) activities by miR-210,
further enhances the ability of HIF-1 to control the
hypoxia-induced metabolic switch to ensure precise control
over energy production and cell survival. In addition,
ectopic expression of miR-328 decreased the deleterious
increase in hypoxia-dependent right ventricular pressure
and pulmonary artery (PA) remodeling.239 Mechanistically,
it was determined that miR-328 inhibits the expression of
the L-type calcium channel-a1c (CaV1.2) and IGF-1R which
are essential for normal smooth muscle and cardiac exci-
tationecontraction coupling240e242 and postnatal hyper-
trophic growth.243 Interestingly, hypoxia induced prolyl-
hydroxylation of Ago2 was found to be a critical determi-
nant in its association with Hsp90, translocation to stress
granules, and miRNA-dependent endonuclease activity,244
suggesting that perturbations in the regulation of miRNA
directed Ago2/RISC activity, in addition to deleterious
changes in miRNA expression, may contribute to molecular
etiology of disease.
Emerging evidence suggests that inappropriate activa-
tion of the STAT3/NFATc2/Pim1 axis has a causal role in
human pulmonary arterial hypertension.245e247 Mesen-
chymal stromal cell derived exosomes (MEX) were found to
inhibit hypoxia induced lung vascular remodeling and
inflammation, right ventricular hypertrophy, and PAH in
mice.248 Mechanistically, it was determined that MEX,
enriched in miR-16, miR-21, and let7b precursor, inhibit
hypoxic induction of the miR-17 superfamily, thereby
increasing the levels of antiproliferative miR-204 expres-
sion to block the STAT3-miR-204-STAT3 feed-forward loop
in distal pulmonary vessels. In addition, miR-328 was found
to directly target Pim1 and to act as a ‘decoy’ sequestering
hnRNP E2 in order to rescue CEBPA mRNA translation.249
Let-7a was found to repress STAT3 activation by targeting
NF2,250 and miR-146b was found to repress STAT3 signaling
by targeting its upstream activators TLR4, MyD88, IRAK-1,
and TRAF6.251 In addition, miR-301a was found to
enhance STAT3 signaling by targeting the STAT3 inhibitor
Pias3,252 while STAT3 dependent miRNA-21 and miR-181b-1
Roles of microRNAs in cardiovascular homeostasis and disease 27were found to be part of a positive feedback look enhancing
STAT3 expression and cellular transformation by targeting
Pten and Cyld respectively .253Subarachnoid and intercerebral haemorrhage
and infarction
Cerebrovascular diseases including atherothrombotic or
embolic infarction (stroke), as well as subarachnoid and
intercerebral hemorrhage was the number 4 cause of death
in the United States from 2009 to 2010, causing approxi-
mately 5.2% of all deaths.1 Of all strokes, 87% are ischemic,
whereas 10% are classified as intercerebral hemorrhage and
w3% are of subarachnoid hemorrhage classification. Among
ischemic stroke survivors 65 years of age from the Fra-
mingham Heart Study, w50% experienced hemiparesis,
w46% had cognitive defects, w19% had aphasia and w26%
were either dependent in daily living activities or institu-
tionalized in a nursing home.3 Rapid diagnosis of stroke and
treatment with antithrombotic or thrombolytic is crucial to
patient survival and subsequent morbidity,254 by minimizing
and preventing neuronal cell death. Post stroke neuronal
cell death is due to cytotoxic edema and/or increased
intracranial cerebral pressure resulting from i) anoxic
membrane depolarization which leads to increased intra-
cellular Naþ, water influx and cellular swelling, and ii)
breakdown of the bloodebrain-barrier leading to indis-
criminate accessibility of intravascular proteins and ions to
the brain parenchyma.255,256
In a rat model of transient focal cerebral ischemia fol-
lowed by reperfusion for 24 or 48 h, the expression level of
multiple miRNAs circulating in the blood and isolated from
the brain were found to be differentially altered,257 sug-
gesting a role for miRNAs in the maintenance of cerebral
homeostasis. Interestingly, many of the dysregulated miR-
NAs are not known to be expressed within the brain or
blood, suggesting that circulating miRNAs may act as mes-
sengers to distal organs/cells following cerebral ische-
miaereperfusion injury. Although women have a lower age-
adjusted stroke incidence than men, women have a longer
lifetime risk of stroke,3 likely due to increased lifespan.
Interestingly, several experimental studies have suggested
that estrogens have neuroprotective effects following
stroke.258e260 In an experimental model of stroke, gender
differences in infarct size have been correlated with miR-
23a (Table 1) expression.261 Post stroke decreases (male)
and increases (female) in miR-23a expression were found to
be linked to infarct size and neuronal apoptosis by targeting
X-linked inhibitor of apoptosis (Xiap), in which the
increased XIAP protein expression (male) inhibits Caspase-3
mediated apoptosis.
Cytotoxic cerebral edema is a major contributor to post-
stroke infarct volume and apoptosis. Aquaporins (MW
w30 kDa) are small integral membrane proteins that are
critical for water transport and are highly expressed in may
cell types of the kidney, lung, and brain that are involved in
fluid transport. Aquaporin 4 (Aqp4) is found to be highly
enriched in perivascular glial processes, the opposite
cellular pole of glial high affinity glutamate transporter
GLAST (Slc1a3), and in subpopulations of ependymal cells
lining the ventricles.262,263 Counter-intuitively, geneticablation of Aqp4 was found to reduce cerebral edema in a
mouse model of human ischemic hemispheric stroke (middle
cerebral artery occlusion),264 leading to increased survival.
Contrary to this observation, intracerebral injection of anti-
miR-320a was found to increase AQP1 and AQP4 expression,
and decrease infarct volume in a mouse model of human
ischemic hemispheric stroke.265 In light of the observations
in Aqp4∕mice, it is appears unlikely that the antagonistic
effects of miR-320a on AQP1 and AQP4 expression are solely
responsible for the reduction in infarct volume, as miR-320
is also known to directly target the cardioprotective and
neural expressed Hsp20 (Hspb6),266,267 metastasis associ-
ated Ets2,Mmp9 and Emilin2,268 pro-angiogenic Nrp1269 and
gycolytic Pfkm.270 In addition, miR-320 was found to recruit
Ago1 and the Polycomb group component Ezh2 to the Polr3d
genetic locus in order to enhance H3K27me3 thereby
repressing Polr3d transcription.271
Glutamate excitotoxicity resulting from increased
glutamate receptor activation is an additional causative
mechanism leading to neuronal cell death. Excessive cal-
cium influx through NMDA receptors requires membrane
depolarization induced by sodium influx through AMPA re-
ceptors.272 Neuronal miR-125b targets NR2A (Grin2a, iono-
tropic glutamate receptor, NMDA receptor subunit epsilon
1) to regulate synapse structure and function,273 while miR-
181a is known to target GluA2/GluR2 (Gria2, ionotropic
glutamate receptor, AMPA receptor subunit alpha 2).274
Interestingly, the bone marrow and spleen enriched miR-
223177 was found to directly target NR2B (Grin2b, ionotropic
glutamate receptor, NMDA receptor subunit epsilon 2) and
GluA2/GluR2 to protect neurons from cell death following
transient global cerebral ischemia.275 Although below the
Northern blot detection threshold,177 quantitative miRNA
RT-PCR analysis indicates that miR-223 is differentially
expressed within the cerebrum, with its highest expression
in the cerebral cortex.275 Interestingly, DAVID (v6.7) and
TargetScan (release 5.1) analyses indicate that the majority
of computationally predicted miR-223 targets are brain
specific, thus raising speculation that the cerebral effects
of miR-223 are from non-neuronal derived miR-223 via
heterocellular signaling.Risk factors for cardiovascular disease
Broadly defined, Metabolic Syndrome (MetS) consists of
multiple risk factors for CVD and type-2 diabetes mellitus
(T2DM) and involves various combinations of dyslipidemia,
hypertension, impaired fasting glucose, insulin resistance,
and increased body mass index (BMI) or waist-to-hip
ratio.276 During 2009 and 2010, the age-adjusted preva-
lence of MetS was 22.9% of the U.S. population.277 Ac-
cording to the National Health and Nutrition Examination
Survey (NHANES) from 2003 to 2006, approximately 34% of
adults met the criteria for MetS.278 Similar to other complex
disorders, multiple genes in various cell types are impli-
cated in the etiology of MetS. Genetic markers identified by
GWAS, genomic SNP analysis, copy-number variants and
compared to clinical risk scores derived from extended
models containing multiple genetic markers for T2DM and
CVD identify i) PPARG, KCNJ11, IGF2BP2, KCNQ1 and SNPs
associated with SLC2A2 and IGF1 correlate highly with
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correlate highly with obesity and insulin resistance.279
Similar to protein coding genes, correlations between
miRNA expression and MetS are observed. Serum miRNA
analysis, genome wide gene expression, and serum NMR
metabolomics analyzed from 71 participants of the Young
Finns Study found that i) miR-144-5p concentration corre-
lated with fasting glucose levels, ii) miR-1207-5p with gly-
cosylated hemoglobin, iii) miR-484 with metabolites
associated with insulin resistance, iv) miR-625-3p with total
and esterified cholesterol, IDL lipids and phospholipids, and
v) miRs-1288-3p, -129-1-3p, -129-2-3p with glycerol.280 In a
3 month study of 21 morbidly obese patients and 14 lean
controls, it was found that the circulating monocyte levels
of miR-181a/b was increased to that of the lean controls in
obese patients following bariatric surgery induced weight
loss.281 Interestingly, the same study identified that miR-
181a levels in monocytes were similarly decreased in a
125 patient cohort diagnosed with MetS and who underwent
coronary angioplasty. MiR-181b (Table 1) is known to
regulate CYLD,253 a deubiquitinating enzyme that nega-
tively regulates NF-kB activity.282,283 Interestingly, miR-181
expression is highest in thymus, brain, lung with noticeable
expression in bone marrow and spleen.177 Together, these
data indicate that plasma or leukocyte-derived miRNAs
contribute to the multitude of causes and consequences of
MetS and CVD; the mechanisms of which are only now
coming into focus.
The peroxisome proliferator-activated receptor g coac-
tivator 1 (PGC-1) family of transcriptional cofactors regu-
late crucial aspects of energy metabolism including
adaptive thermogenesis in brown adipose tissue, adipocyte
cell fate determination, mitochondrial biogenesis, glucose
uptake and gluconeogenesis.284,285 Encoded within PGC1a,
miRs-378 and -378* were found to counter the metabolic
actions of PGC1a through repression of carnitine O-acetyl-
transferase (CRAT) and MED13.286 CRAT encodes a mito-
chondrial enzyme involved in fatty acid metabolism and
MED13 is a component of the Mediator complex controlling
nuclear hormone receptor activity. Interestingly, pharma-
cological inhibition of miR-208a and cardiac specific MED13
transgenic mice displayed similar resistance to obesity and
glucose intolerance after 6 weeks of a high fat diet.287 In
addition, cardiac specific deletion of MED13 enhanced
susceptibility to obesity following 6 weeks of a high fat
diet. Cardiac specific miR-208a is known to target MED13/
THRAP1/TRAP240.67,68 Together these data indicate a
critical role of cardiac miR-208a and MED13 in the regula-
tion of systemic energy homeostasis and whole body
metabolism; however, the heterocellular signaling mecha-
nism linking cardiac miR-208a/MED13 to white adipose tis-
sue accumulation and glucose tolerance remains to be
identified. MiR-21 knockout mice and inhibition of miR-21 in
WT mice have reduced kidney fibrosis and epithelial injury
in unilateral ureteral obstruction and unilateral ischemia
reperfusion injury models of kidney injury.64 Mechanisti-
cally, it was determined that miR-21 targets peroxisome
proliferator-activated receptor a (Ppara), a transcription
factor that regulates multiple metabolic and lipid oxidation
pathways, and Mpv17l (also known as M-LP), an inner
mitochondrial membrane protein which inhibits mitochon-
drial oxidative stress.288,289A causal link between insulin resistance and macrophage
activation (see Atherosclerosis) has been elucidated. Ge-
netic ablation of the bone marrow macrophage enriched
miR-223 was found to exacerbate high-fat diet induced in-
sulin resistance macrophage activation/polarization
through repression of Pknox1.290 Importantly, a bone
marrow transplant from miR-223∕ mice into WT mice
demonstrated that myeloid cell-specific loss of miR-223 was
sufficient to exacerbate systemic insulin resistance and
adipose tissue inflammation. Significantly repressed in ad-
ipocytes of obese patients, miR-130a/b was found to
repress adipocyte differentiation by targeting peroxisome
proliferator-activated receptor g (Pparg).291 Interestingly,
the induction of miR-130a/b expression in differentiated
adipocytes in response to TNFa stimulation is partially due
to NF-kB enhanced transcription,292 further suggesting
cross-talk between pro-inflammatory signaling and insulin
resistance. In addition, silencing of miR-103/107 (miRs-103
and -107 differ by one nucleotide at position 21) alleviates
hyperglycemia in ob/ob and diet-induced obese mice.293 Of
potential therapeutic interest, it was further demonstrated
that hepatic silencing of miR-103/107 expression is i) suf-
ficient to reverse metabolic abnormalities in obese and
insulin-resistant states, and ii) directly leads to increased
Cav1 levels and subsequent improvements in insulin
signaling by increased adipocyte insulin receptor b-subunit
(IRb) expression and increased insulin dependent phos-
phorylation of Akt1 and IRb in adipose tissue and the liver.
Perhaps most interestingly, miRNAs similarly play a
regulatory role in the production of insulin in response to a
variety of physiological stimuli. The pancreatic b-cell
enriched miR-375 was found to target myotrophin (Mtpn)
and vesicle transport through interaction with t-SNAREs 1A
(Vti1a) and in order to repress glucose induced insulin
secretion.294 Myotrophin and VTI1A are known to be
involved in cardiac hypertrophy295,296 as well as neuronal
vesicular transport and neurotransmitter release.297
Importantly, miR-375 null mice are hyperglycemic with
elevated gluconeogenesis and hepatic glucose output.298
Interestingly, it was discovered that these mice have
reduced b-cell mass due to impaired b-cell proliferation
likely due to elevated expression of cell adhesion molecule
1 (Cadm1), gephyrin (Gphn), caveolin1 (Cav1), inhibitor of
DNA binding 3 (Id3), Smarca2, Rasedexamethasone-
induced-1 (Rasd1), and mitochondrion-associated
apoptosis-inducing factor 1 (Aifm1). Interestingly, b-cell
thioredoxin-interacting protein (TXNIP) was found to induce
the expression of miR-204, thereby repressing MAFA
expression and insulin transcription.299 MAFA is a basic
leucine zipper transcription factor that is essential for
glucose induced insulin secretion, but regulating the tran-
scription of insulin.300 Further, it was found that miR-143/
145 null mice are protected from the development of
T2DM, whereas transgenic overexpression of miR-143, but
not miR-145, impaired insulin induced AKT activation and
glucose homeostasis.301 Mechanistically, it was found that
the expression of miR-143/145 was dramatically elevated in
the livers of obese mice lead to the miR-143 directed in-
hibition of oxysterol-binding-protein-related protein (ORP)
8.302 Loss of pancreatic b-cell number is a critical factor in
the etiology of diabetes, and a subject of targeted thera-
peutic research.303,304 It is becoming evident that miRNAs
Roles of microRNAs in cardiovascular homeostasis and disease 29are key regulators of metabolic pathways contributing to
CVD.
Conclusions and future directions
In this review we have attempted to summarize what is
known regarding molecular mechanisms whereby miRNAs
modulate normal physiological and pathophysiological sig-
nals within the cardiovascular system. A complex model has
evolved in which miRNAs modulate key regulatory pro-
cesses involved in fine-tuning signal transduction cascades,
thereby maintaining cellular and physiological homeostasis
(Fig. 2). This complexity is readily apparent from the mul-
tiple lines of evidence indicating the essential roles of
miRNAs in the regulation of i) cytokine/paracrine/auto-
crine signaling, ii) lipid metabolism and the progression of
atherosclerosis, iii) resting membrane potential and intra-
cellular calcium handling, and iv) hematopoietic derivedFigure 2 Known heterocellular signaling mechanisms involved in t
known about multiple cell types within the cardiovascular system
The information presented above represents findings from multiple
disease models were utilized to determine the biological and physinflammatory cells in the progression of atherosclerosis and
cardiac hypertrophy. In addition, from multiple genetic
mouse models, we have learned of the critical roles that
miRNAs play in normal development, physiological homeo-
stasis, and cellular responses to pathological stimuli.
Importantly, these data indicate the necessity of miRNAs in
maintaining physiological homeostasis by directly modu-
lating plasma HDL/LDL ratios, inflammatory cytokine pro-
duction and signaling, systemic energy homeostasis and
MetS, mitochondrial function, cellular proliferation,
apoptosis, as well as ECM deposition and remodeling.
However, confounding many of these results is the discov-
ery that non-cell-autonomous miRNAs contribute to post-
transcriptional gene regulation. While the relative contri-
bution of non-cell-autonomous vs. cell-autonomous miRNAs
remains to be determined, heterocellular communication
via miRNAs is emerging as a physiologically relevant
signaling paradigm.he progression of CVD. This figure summarizes what is currently
under normal physiological and pathophysiological conditions.
in vivo and in vitro experimental models in which genetic and
iological function of miRNAs.
30 R.L. Neppl, D.-Z. WangDespite compelling evidence identifying post-
transcriptional targets of individual miRNAs, and the path-
ophysiological effects of abrogating miRNA directed mRNA
translational repression, we know relatively little about
how multiple miRNAs work in concert, how polycistronic
miRNAs are regulated, or if cells are capable of discrimi-
nating between cell-autonomous and non-cell-autonomous
miRNAs. Key unresolved questions include the following: 1)
Do non-cell-autonomous miRNAs supplant or complement
cell-autonomous miRNAs? 2) Do multiple miRNA loaded
RISCs compete or complement their biochemical activities
with respect to a single mRNA? 3) Do non-cell-autonomous
miRNA passenger strands act as a sponge for cell-
autonomous derived miRNA target strands or do they
participate in RISC loading and translational repression? 4)
What are the environmental cues and extracellular stimuli
that regulate the ratios of mature miRNAs derived from
polycistrons? 5) What are the cellular origins of the miRNAs
found to be circulating within blood? 6) How is the
expression of these circulating miRNAs regulated under
multifactorial diseases such as MetS, diabetes, hyperten-
sion, dyslipidemia and atherosclerosis?
Clearly, there has been much exciting progress in our
understanding of signaling cascades regulated by miRNAs
and their contribution to the etiology of CVD, but additional
work is needed. Given that CVD is a multifactorial disease
process involving not just the heart and vasculature, but
also bone marrow derived cells, liver regulation of plasma
lipids, and pancreatic insulin signaling among others, it is
likely that major progress in this area is going to be
dependent upon sophisticated cell-type specific loss of
function approaches coupled with whole animal physiolog-
ical studies and/or local inhibition of candidate regulatory
factors. Finally, much additional work is also needed to
identify dysregulated miRNAs, which are both causative and
specific, for diagnosis/prognosis of end-stage clinical
sequelae of hypertension, atherosclerosis, myocardial
infarction and cardiac hypertrophy.
Conflict of interest
The authors declare no conflicts of interest.References
1. Heron M. Deaths: leading causes for 2010. Natl Vital Stat Rep.
Dec 2013;62(6):1e97.
2. Yang Q, Cogswell ME, Flanders WD, Hong Y, Zhang Z,
Loustalot F, et al. Trends in cardiovascular health metrics and
associations with all-cause and CVD mortality among US
adults. JAMA. Mar 28 2012;307(12):1273e1283.
3. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD,
Blaha MJ, et al. Heart disease and stroke statisticse2014
update: a report from the American Heart Association. Cir-
culation. Jan 21 2014;129(3):e28ee292.
4. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K,
Ezekowitz MD, et al. Forecasting the future of cardiovascular
disease in the United States: a policy statement from the
American Heart Association. Circulation. Mar 1 2011;123(8):
933e944.
5. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC.
Potent and specific genetic interference by double-strandedRNA in Caenorhabditis elegans. Nature. Feb 19 1998;
391(6669):806e811.
6. Tabara H, Sarkissian M, Kelly WG, Fleenor J, Grishok A,
Timmons L, et al. The rde-1 gene, RNA interference, and trans-
poson silencing in C. elegans. Cell. Oct 15 1999;99(2):123e132.
7. Fire A, Albertson D, Harrison SW, Moerman DG. Production of
antisense RNA leads to effective and specific inhibition of
gene expression in C. elegans muscle. Dev Camb Engl. Oct
1991;113(2):503e514.
8. Ambros V. microRNAs: tiny regulators with great potential.
Cell. Dec 28 2001;107(7):823e826.
9. Lee RC, Ambros V. An extensive class of small RNAs in Cae-
norhabditis elegans. Sci New York, N.Y. Oct 26 2001;
294(5543):862e864.
10. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic
gene lin-4 encodes small RNAs with antisense complemen-
tarity to lin-14. Cell. Dec 3 1993;75(5):843e854.
11. Giraldez AJ, Cinalli RM, Glasner ME, Enright AJ, Thomson JM,
Baskerville S, et al. MicroRNAs regulate brain morphogenesis
in zebrafish. Sci New York, N.Y. May 6 2005;308(5723):
833e838.
12. Decembrini S, Bressan D, Vignali R, Pitto L, Mariotti S,
Rainaldi G, et al. MicroRNAs couple cell fate and develop-
mental timing in retina. Proc Natl Acad Sci U S A. Dec 15 2009;
106(50):21179e21184.
13. Huang ZP, Chen JF, Regan JN, Maguire CT, Tang RH, Dong XR,
et al. Loss of microRNAs in neural crest leads to cardiovas-
cular syndromes resembling human congenital heart defects.
Arteriosclerosis, Thrombosis, Vasc Biology. Dec 2010;30(12):
2575e2586.
14. Ebert MS, Sharp PA. Roles for microRNAs in conferring
robustness to biological processes. Cell. Apr 27 2012;149(3):
515e524.
15. Cheung TH, Quach NL, Charville GW, Liu L, Park L, Edalati A,
et al. Maintenance of muscle stem-cell quiescence by
microRNA-489. Nature. Feb 23 2012;482(7386):524e528.
16. Divakaran V, Mann DL. The emerging role of microRNAs in
cardiac remodeling and heart failure. Circ Res. Nov 7 2008;
103(10):1072e1083.
17. Calin GA, Croce CM. MicroRNA signatures in human cancers.
Nat Rev Cancer. Nov 2006;6(11):857e866.
18. Mendell JT, Olson EN. MicroRNAs in stress signaling and human
disease. Cell. Mar 16 2012;148(6):1172e1187.
19. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogo-
sova-Agadjanyan EL, et al. Circulating microRNAs as stable
blood-based markers for cancer detection. Proc Natl Acad Sci
U S A. Jul 29 2008;105(30):10513e10518.
20. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP,
Pulford K, et al. Detection of elevated levels of tumour-
associated microRNAs in serum of patients with diffuse large
B-cell lymphoma. Br J Haematol. May 2008;141(5):672e675.
21. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Character-
ization of microRNAs in serum: a novel class of biomarkers for
diagnosis of cancer and other diseases. Cell Res. Oct 2008;
18(10):997e1006.
22. Ambros V. The functions of animal microRNAs. Nature. Sep 16
2004;431(7006):350e355.
23. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and
function. Cell. Jan 23 2004;116(2):281e297.
24. Bartel DP. MicroRNAs: target recognition and regulatory
functions. Cell. Jan 23 2009;136(2):215e233.
25. Czech B, Hannon GJ. Small RNA sorting: matchmaking for
Argonautes. Nat Rev Genet. Jan 2011;12(1):19e31.
26. Djuranovic S, Nahvi A, Green R. A parsimonious model for
gene regulation by miRNAs. Sci New York, N.Y. Feb 4 2011;
331(6017):550e553.
27. Kim VN. MicroRNA biogenesis: coordinated cropping and
dicing. Nat Rev. May 2005;6(5):376e385.
Roles of microRNAs in cardiovascular homeostasis and disease 3128. Rana TM. Illuminating the silence: understanding the struc-
ture and function of small RNAs. Nat Rev. Jan 2007;8(1):
23e36.
29. Garcia-Garcia C, Subirana I, Sala J, Bruguera J, Sanz G,
Valle V, et al. Long-term prognosis of first myocardial
infarction according to the electrocardiographic pattern (ST
elevation myocardial infarction, non-ST elevation myocardial
infarction and non-classified myocardial infarction) and
revascularization procedures. Am J Cardiol. Oct 15 2011;
108(8):1061e1067.
30. Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y,
Hofstra L, et al. Circulating MicroRNA-208b and MicroRNA-499
reflect myocardial damage in cardiovascular disease. Circ
Cardiovasc Genet. Dec 2010;3(6):499e506.
31. Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, et al. Circulating
microRNA: a novel potential biomarker for early diagnosis of
acute myocardial infarction in humans. Eur heart J. Mar 2010;
31(6):659e666.
32. Adachi T, Nakanishi M, Otsuka Y, Nishimura K, Hirokawa G,
Goto Y, et al. Plasma microRNA 499 as a biomarker of acute
myocardial infarction. Clin Chem. Jul 2010;56(7):
1183e1185.
33. D’Alessandra Y, Devanna P, Limana F, Straino S, Di Carlo A,
Brambilla PG, et al. Circulating microRNAs are new and sen-
sitive biomarkers of myocardial infarction. Eur heart J. Nov
2010;31(22):2765e2773.
34. Olivieri F, Antonicelli R, Spazzafumo L, Santini G, Rippo MR,
Galeazzi R, et al. Admission levels of circulating miR-499-5p
and risk of death in elderly patients after acute non-ST
elevation myocardial infarction. Int J Cardiol. Mar 15 2014;
172(2):e276e278.
35. van Rooij E, Quiat D, Johnson BA, Sutherland LB, Qi X,
Richardson JA, et al. A family of microRNAs encoded by
myosin genes governs myosin expression and muscle perfor-
mance. Dev Cell. Nov 2009;17(5):662e673.
36. Steg PG, Dabbous OH, Feldman LJ, Cohen-Solal A,
Aumont MC, Lopez-Sendon J, et al. Determinants and prog-
nostic impact of heart failure complicating acute coronary
syndromes: observations from the Global Registry of Acute
Coronary Events (GRACE). Circulation. Feb 3 2004;109(4):
494e499.
37. Ezekowitz JA, Kaul P, Bakal JA, Armstrong PW, Welsh RC,
McAlister FA. Declining in-hospital mortality and increasing
heart failure incidence in elderly patients with first myocar-
dial infarction. J Am Coll Cardiol. Jan 6 2009;53(1):13e20.
38. Kannel WB, Sorlie P, McNamara PM. Prognosis after initial
myocardial infarction: the Framingham study. Am J Cardiol.
Jul 1979;44(1):53e59.
39. Matsumoto S, Sakata Y, Suna S, Nakatani D, Usami M, Hara M,
et al. Circulating p53-responsive microRNAs are predictive
indicators of heart failure after acute myocardial infarction.
Circ Res. Jul 19 2013;113(3):322e326.
40. Matsumoto S, Sakata Y, Nakatani D, Suna S, Mizuno H,
Shimizu M, et al. A subset of circulating microRNAs are pre-
dictive for cardiac death after discharge for acute myocardial
infarction. Biochem biophysical Res Commun. Oct 19 2012;
427(2):280e284.
41. Kardasinski M, Thum T. Cardiac fibroblasts on the fast
trackescleraxis: from Achilles’ heel to anti-fibrotic therapy. J
Mol Cell Cardiol. Aug 2009;47(2):174e176.
42. Bosman FT, Stamenkovic I. Functional structure and compo-
sition of the extracellular matrix. J Pathol. Jul 2003;200(4):
423e428.
43. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA.
Myofibroblasts and mechano-regulation of connective tissue
remodelling. Nat Rev Mol Cell Biol. May 2002;3(5):349e363.
44. Swynghedauw B. Molecular mechanisms of myocardial
remodeling. Physiol Rev. Jan 1999;79(1):215e262.45. Braunwald E. Heart failure. JACC Heart Fail. Feb 2013;1(1):
1e20.
46. Jugdutt BI. Ventricular remodeling after infarction and the
extracellular collagen matrix: when is enough enough? Cir-
culation. Sep 16 2003;108(11):1395e1403.
47. Thambo JB, Bordachar P, Garrigue S, Lafitte S, Sanders P,
Reuter S, et al. Detrimental ventricular remodeling in pa-
tients with congenital complete heart block and chronic right
ventricular apical pacing. Circulation. Dec 21 2004;110(25):
3766e3772.
48. Haddad F, Hunt SA, Rosenthal DN, Murphy DJ. Right ventric-
ular function in cardiovascular disease, part I: Anatomy,
physiology, aging, and functional assessment of the right
ventricle. Circulation. Mar 18 2008;117(11):1436e1448.
49. Zornoff LA, Skali H, Pfeffer MA, St John Sutton M, Rouleau JL,
Lamas GA, et al. Right ventricular dysfunction and risk of
heart failure and mortality after myocardial infarction. J Am
Coll Cardiol. May 1 2002;39(9):1450e1455.
50. da Costa Martins PA, Bourajjaj M, Gladka M, Kortland M, van
Oort RJ, Pinto YM, et al. Conditional dicer gene deletion in
the postnatal myocardium provokes spontaneous cardiac
remodeling. Circulation. Oct 7 2008;118(15):1567e1576.
51. Kato M, Zhang J, Wang M, Lanting L, Yuan H, Rossi JJ, et al.
MicroRNA-192 in diabetic kidney glomeruli and its function in
TGF-beta-induced collagen expression via inhibition of E-box
repressors. Proc Natl Acad Sci U S A. Feb 27 2007;104(9):
3432e3437.
52. Bernardo BC, Gao XM, Winbanks CE, Boey EJ, Tham YK,
Kiriazis H, et al. Therapeutic inhibition of the miR-34 family
attenuates pathological cardiac remodeling and improves
heart function. Proc Natl Acad Sci U S A. Oct 23 2012;109(43):
17615e17620.
53. Boon RA, Iekushi K, Lechner S, Seeger T, Fischer A, Heydt S,
et al. MicroRNA-34a regulates cardiac ageing and function.
Nature. Mar 7 2013;495(7439):107e110.
54. Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, van
der Made I, et al. miR-133 and miR-30 regulate connective
tissue growth factor: implications for a role of microRNAs in
myocardial matrix remodeling. Circ Res. Jan 30 2009;104(2):
170e178, 176pp. following 178.
55. Matkovich SJ, Wang W, Tu Y, Eschenbacher WH, Dorn LE,
Condorelli G, et al. MicroRNA-133a protects against myocar-
dial fibrosis and modulates electrical repolarization without
affecting hypertrophy in pressure-overloaded adult hearts.
Circ Res. Jan 8 2010;106(1):166e175.
56. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM,
Naseem RH, Marshall WS, et al. Dysregulation of microRNAs
after myocardial infarction reveals a role of miR-29 in cardiac
fibrosis. Proc Natl Acad Sci U S A. Sep 2 2008;105(35):
13027e13032.
57. Dawson K, Wakili R, Ordog B, Clauss S, Chen Y, Iwasaki Y,
et al. MicroRNA29: a mechanistic contributor and potential
biomarker in atrial fibrillation. Circ Apr 9. 2013;127(14):
1466e1475, 1475e1461-1428.
58. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M,
et al. MicroRNA-21 contributes to myocardial disease by
stimulating MAP kinase signalling in fibroblasts. Nature. Dec
18 2008;456(7224):980e984.
59. Bronnum H, Andersen DC, Schneider M, Sandberg MB,
Eskildsen T, Nielsen SB, et al. miR-21 promotes fibrogenic
epithelial-to-mesenchymal transition of epicardial mesothe-
lial cells involving Programmed Cell Death 4 and Sprouty-1.
PLoS One. 2013;8(2):e56280.
60. Zhang Z, Zha Y, Hu W, Huang Z, Gao Z, Zang Y, et al. The
autoregulatory feedback loop of microRNA-21/programmed
cell death protein 4/activation protein-1 (MiR-21/PDCD4/AP-
1) as a driving force for hepatic fibrosis development. J Biol
Chem. Dec 27 2013;288(52):37082e37093.
32 R.L. Neppl, D.-Z. Wang61. Roy S, Khanna S, Hussain SR, Biswas S, Azad A, Rink C, et al.
MicroRNA expression in response to murine myocardial
infarction: miR-21 regulates fibroblast metalloprotease-2 via
phosphatase and tensin homologue. Cardiovasc Res. Apr 1
2009;82(1):21e29.
62. Kato M, Putta S, Wang M, Yuan H, Lanting L, Nair I, et al. TGF-
beta activates Akt kinase through a microRNA-dependent
amplifying circuit targeting PTEN. Nat Cell Biol. Jul 2009;
11(7):881e889.
63. Kumarswamy R, Volkmann I, Jazbutyte V, Dangwal S, Park DH,
Thum T. Transforming growth factor-beta-induced endothe-
lial-to-mesenchymal transition is partly mediated by micro-
RNA-21. Arteriosc Thromb Vasc biology. Feb 2012;32(2):
361e369.
64. Chau BN, Xin C, Hartner J, Ren S, Castano AP, Linn G, et al.
MicroRNA-21 promotes fibrosis of the kidney by silencing
metabolic pathways. Sci Transl Med. Feb 15 2012;4(121):
121ra118.
65. Bang C, Batkai S, Dangwal S, Gupta SK, Foinquinos A,
Holzmann A, et al. Cardiac fibroblast-derived microRNA pas-
senger strand-enriched exosomes mediate cardiomyocyte
hypertrophy. J Clin Invest. Apr 17 2014;124(5):2136e2146.
66. Patrick DM, Montgomery RL, Qi X, Obad S, Kauppinen S,
Hill JA, et al. Stress-dependent cardiac remodeling occurs in
the absence of microRNA-21 in mice. J Clin Invest. Nov 2010;
120(11):3912e3916.
67. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J,
Olson EN. Control of stress-dependent cardiac growth and
gene expression by a microRNA. Sci New York, N.Y. Apr 27
2007;316(5824):575e579.
68. Callis TE, Pandya K, Seok HY, Tang RH, Tatsuguchi M,
Huang ZP, et al. MicroRNA-208a is a regulator of cardiac hy-
pertrophy and conduction in mice. J Clin Invest. Sep 2009;
119(9):2772e2786.
69. Montgomery RL, Hullinger TG, Semus HM, Dickinson BA,
Seto AG, Lynch JM, et al. Therapeutic inhibition of miR-208a
improves cardiac function and survival during heart failure.
Circulation. Oct 4 2011;124(14):1537e1547.
70. Matkovich SJ, Hu Y, Eschenbacher WH, Dorn LE, Dorn 2nd GW.
Direct and indirect involvement of microRNA-499 in clinical
and experimental cardiomyopathy. Circ Res. Aug 17 2012;
111(5):521e531.
71. D’Angelo DD, Sakata Y, Lorenz JN, Boivin GP, Walsh RA,
Liggett SB, et al. Transgenic Galphaq overexpression induces
cardiac contractile failure in mice. Proc Natl Acad Sci U S A.
Jul 22 1997;94(15):8121e8126.
72. Adams JW, Sakata Y, Davis MG, Sah VP, Wang Y, Liggett SB,
et al. Enhanced Galphaq signaling: a common pathway me-
diates cardiac hypertrophy and apoptotic heart failure. Proc
Natl Acad Sci U S A. Aug 18 1998;95(17):10140e10145.
73. Bell ML, Buvoli M, Leinwand LA. Uncoupling of expression of
an intronic microRNA and its myosin host gene by exon skip-
ping. Mol Cell Biol. Apr 2010;30(8):1937e1945.
74. Wang JX, Jiao JQ, Li Q, Long B, Wang K, Liu JP, et al. miR-499
regulates mitochondrial dynamics by targeting calcineurin
and dynamin-related protein-1. Nat Med. Jan 2011;17(1):
71e78.
75. Kolwicz Jr SC, Purohit S, Tian R. Cardiac metabolism and its
interactions with contraction, growth, and survival of car-
diomyocytes. Circ Res. Aug 16 2013;113(5):603e616.
76. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH,
Taegtmeyer H. Metabolic gene expression in fetal and failing
human heart. Circulation. Dec 11 2001;104(24):2923e2931.
77. Wang K, Long B, Jiao JQ, Wang JX, Liu JP, Li Q, et al. miR-484
regulates mitochondrial network through targeting Fis1. Nat
Commun. 2012;3:781.
78. Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y,
Nguyen A, et al. miR-380-5p represses p53 to control cellularsurvival and is associated with poor outcome in MYCN-ampli-
fied neuroblastoma. Nat Med. Oct 2010;16(10):1134e1140.
79. el Azzouzi H, Leptidis S, Dirkx E, Hoeks J, van Bree B, Brand K,
et al. The hypoxia-inducible microRNA cluster miR-199a
approximately 214 targets myocardial PPARdelta and impairs
mitochondrial fatty acid oxidation. Cell metab. Sep 3 2013;
18(3):341e354.
80. Aurora AB, Mahmoud AI, Luo X, Johnson BA, van Rooij E,
Matsuzaki S, et al. MicroRNA-214 protects the mouse heart
from ischemic injury by controlling Ca(2)(+) overload and cell
death. J Clin Invest. Apr 2 2012;122(4):1222e1232.
81. Yang B, Lin H, Xiao J, Lu Y, Luo X, Li B, et al. The muscle-
specific microRNA miR-1 regulates cardiac arrhythmogenic
potential by targeting GJA1 and KCNJ2. Nat Med. Apr 2007;
13(4):486e491.
82. Terentyev D, Belevych AE, Terentyeva R, Martin MM,
Malana GE, Kuhn DE, et al. miR-1 overexpression enhances
Ca2+ release and promotes cardiac Arrhythmogenesis by tar-
geting PP2A regulatory subunit B56{alpha} and Causing CaM-
KII-dependent Hyperphosphorylation of RyR2. Circ Res. Jan 8
2009;104(4):514e521.
83. Wahlquist C, Jeong D, Rojas-Munoz A, Kho C, Lee A,
Mitsuyama S, et al. Inhibition of miR-25 improves cardiac
contractility in the failing heart. Nature. Apr 24 2014;
508(7497):531e535.
84. Lu Y, Zhang Y, Wang N, Pan Z, Gao X, Zhang F, et al. MicroRNA-
328 contributes to adverse electrical remodeling in atrial
fibrillation. Circulation. Dec 7 2010;122(23):2378e2387.
85. Nattel S. New ideas about atrial fibrillation 50 years on. Na-
ture. Jan 10 2002;415(6868):219e226.
86. Nattel S, Maguy A, Le Bouter S, Yeh YH. Arrhythmogenic ion-
channel remodeling in the heart: heart failure, myocardial
infarction, and atrial fibrillation. Physiol Rev. Apr 2007;87(2):
425e456.
87. Van Wagoner DR, Pond AL, Lamorgese M, Rossie SS,
McCarthy PM, Nerbonne JM. Atrial L-type Ca2+ currents and
human atrial fibrillation. Circ Res. Sep 3 1999;85(5):428e436.
88. Chou CC, Nihei M, Zhou S, Tan A, Kawase A, Macias ES, et al.
Intracellular calcium dynamics and anisotropic reentry in
isolated canine pulmonary veins and left atrium. Circulation.
Jun 7 2005;111(22):2889e2897.
89. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M. MicroRNAs
play an essential role in the development of cardiac hyper-
trophy. Circ Res. Feb 16 2007;100(3):416e424.
90. Luo X, Pan Z, Shan H, Xiao J, Sun X, Wang N, et al. MicroRNA-
26 governs profibrillatory inward-rectifier potassium current
changes in atrial fibrillation. J Clin Invest. May 1 2013;123(5):
1939e1951.
91. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy
by intracellular signalling pathways. Nat Rev Mol Cell Biol.
Aug 2006;7(8):589e600.
92. Vega RB, Bassel-Duby R, Olson EN. Control of cardiac growth
and function by calcineurin signaling. J Biol Chem. Sep 26
2003;278(39):36981e36984.
93. da Costa Martins PA, Salic K, Gladka MM, Armand AS,
Leptidis S, el Azzouzi H, et al. MicroRNA-199b targets the
nuclear kinase Dyrk1a in an auto-amplification loop promoting
calcineurin/NFAT signalling. Nat Cell Biol. Dec 2010;12(12):
1220e1227.
94. Dirkx E, Gladka MM, Philippen LE, Armand AS, Kinet V,
Leptidis S, et al. Nfat and miR-25 cooperate to reactivate the
transcription factor Hand2 in heart failure. Nat Cell Biol. Nov
2013;15(11):1282e1293.
95. Lin Z, Murtaza I, Wang K, Jiao J, Gao J, Li PF. miR-23a func-
tions downstream of NFATc3 to regulate cardiac hypertrophy.
Proc Natl Acad Sci U S A. Jul 21 2009;106(29):12103e12108.
96. Seok HY, Chen J, Kataoka M, Huang ZP, Ding J, Yan J, et al.
Loss of microRNA-155 protects the heart from pathological
Roles of microRNAs in cardiovascular homeostasis and disease 33cardiac hypertrophy. Circ Res. Mar 21 2014;114(10):
1585e1595.
97. Pasini D, Cloos PA, Walfridsson J, Olsson L, Bukowski JP,
Johansen JV, et al. JARID2 regulates binding of the Polycomb
repressive complex 2 to target genes in ES cells. Nature. Mar
11 2010;464(7286):306e310.
98. Peng JC, Valouev A, Swigut T, Zhang J, Zhao Y, Sidow A, et al.
Jarid2/Jumonji coordinates control of PRC2 enzymatic ac-
tivity and target gene occupancy in pluripotent cells. Cell.
Dec 24 2009;139(7):1290e1302.
99. Heymans S, Corsten MF, Verhesen W, Carai P, van
Leeuwen RE, Custers K, et al. Macrophage microRNA-155
promotes cardiac hypertrophy and failure. Circulation. Sep 24
2013;128(13):1420e1432.
100. Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P,
Soond DR, et al. Requirement of bic/microRNA-155 for normal
immune function. Sci New York, N.Y. Apr 27 2007;316(5824):
608e611.
101. Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, et al.
Regulation of the germinal center response by microRNA-155.
Sci New York, N.Y. Apr 27 2007;316(5824):604e608.
102. Ucar A, Gupta SK, Fiedler J, Erikci E, Kardasinski M, Batkai S,
et al. The miRNA-212/132 family regulates both cardiac hy-
pertrophy and cardiomyocyte autophagy. Nat Commun. 2012;
3:1078.
103. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A,
et al. Foxo transcription factors induce the atrophy-related
ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy.
Cell. Apr 30 2004;117(3):399e412.
104. Li HH, Kedar V, Zhang C, McDonough H, Arya R, Wang DZ,
et al. Atrogin-1/muscle atrophy F-box inhibits calcineurin-
dependent cardiac hypertrophy by participating in an SCF
ubiquitin ligase complex. J Clin Invest. Oct 2004;114(8):
1058e1071.
105. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE,
Hammond SM, et al. The role of microRNA-1 and microRNA-
133 in skeletal muscle proliferation and differentiation. Nat
Genet. Feb 2006;38(2):228e233.
106. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P,
et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med.
May 2007;13(5):613e618.
107. Karakikes I, Chaanine AH, Kang S, Mukete BN, Jeong D,
Zhang S, et al. Therapeutic cardiac-targeted delivery of miR-1
reverses pressure overload-induced cardiac hypertrophy and
attenuates pathological remodeling. J Am Heart Assoc. Apr
2013;2(2):e000078.
108. Brown JH, Del Re DP, Sussman MA. The Rac and Rho hall of
fame: a decade of hypertrophic signaling hits. Circ Res. Mar
31 2006;98(6):730e742.
109. Nagai T, Tanaka-Ishikawa M, Aikawa R, Ishihara H, Zhu W,
Yazaki Y, et al. Cdc42 plays a critical role in assembly of
sarcomere units in series of cardiac myocytes. Biochem Bio-
phys Res Commun. Jun 13 2003;305(4):806e810.
110. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of
vascular smooth muscle cell differentiation in development
and disease. Physiol Rev. Jul 2004;84(3):767e801.
111. Ross R. The pathogenesis of atherosclerosis: a perspective for
the 1990s. Nature. Apr 29 1993;362(6423):801e809.
112. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL,
Edwards PA, et al. Atherosclerosis: basic mechanisms.
Oxidation, inflammation, and genetics. Circulation. May 1
1995;91(9):2488e2496.
113. Berliner JA, Watson AD. A role for oxidized phospholipids in
atherosclerosis. N. Engl J Med. Jul 7 2005;353(1):9e11.
114. Kannel WB, Castelli WP, Gordon T. Cholesterol in the pre-
diction of atherosclerotic disease. New perspectives based on
the Framingham study. Ann Intern Med. Jan 1979;90(1):
85e91.115. Libby P. Inflammation in atherosclerosis. Nature. Dec 19-26
2002;420(6917):868e874.
116. Libby P, Ridker PM, Maseri A. Inflammation and atheroscle-
rosis. Circ. Mar 5 2002;105(9):1135e1143.
117. Hansson GK. Inflammation, atherosclerosis, and coronary
artery disease. N. Engl J Med. Apr 21 2005;352(16):
1685e1695.
118. Kovanen PT, Kaartinen M, Paavonen T. Infiltrates of activated
mast cells at the site of coronary atheromatous erosion or
rupture in myocardial infarction. Circ Sep. 1995;92(5):
1084e1088.
119. Hansson GK, Holm J, Jonasson L. Detection of activated T
lymphocytes in the human atherosclerotic plaque. Am J
Pathol. Jul 1989;135(1):169e175.
120. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of
intimal rupture or erosion of thrombosed coronary athero-
sclerotic plaques is characterized by an inflammatory process
irrespective of the dominant plaque morphology. Circulation.
Jan 1994;89(1):36e44.
121. Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, et al. A
major role for VCAM-1, but not ICAM-1, in early atheroscle-
rosis. J Clin Invest. May 2001;107(10):1255e1262.
122. Fang Y, Shi C, Manduchi E, Civelek M, Davies PF. MicroRNA-10a
regulation of proinflammatory phenotype in athero-suscepti-
ble endothelium in vivo and in vitro. Proc Natl Acad Sci U S A.
Jul 27 2010;107(30):13450e13455.
123. Zhou J, Wang KC, Wu W, Subramaniam S, Shyy JY, Chiu JJ,
et al. MicroRNA-21 targets peroxisome proliferators-activated
receptor-alpha in an autoregulatory loop to modulate flow-
induced endothelial inflammation. Proc Natl Acad Sci U S A.
Jun 21 2011;108(25):10355e10360.
124. Wu W, Xiao H, Laguna-Fernandez A, Villarreal Jr G, Wang KC,
Geary GG, et al. Flow-Dependent regulation of Kruppel-like
factor 2 is mediated by MicroRNA-92a. Circulation. Aug 2
2011;124(5):633e641.
125. Wang KC, Garmire LX, Young A, Nguyen P, Trinh A,
Subramaniam S, et al. Role of microRNA-23b in flow-regula-
tion of Rb phosphorylation and endothelial cell growth. Proc
Natl Acad Sci U S A. Feb 16 2010;107(7):3234e3239.
126. Hergenreider E, Heydt S, Treguer K, Boettger T,
Horrevoets AJ, Zeiher AM, et al. Atheroprotective communi-
cation between endothelial cells and smooth muscle cells
through miRNAs. Nat Cell Biol. Mar 2012;14(3):249e256.
127. Boettger T, Beetz N, Kostin S, Schneider J, Kruger M, Hein L,
et al. Acquisition of the contractile phenotype by murine
arterial smooth muscle cells depends on the Mir143/145 gene
cluster. J Clin Invest. Sep 2009;119(9):2634e2647.
128. Xin M, Small EM, Sutherland LB, Qi X, McAnally J, Plato CF,
et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal
dynamics and responsiveness of smooth muscle cells to injury.
Genes & development. Sep 15 2009;23(18):2166e2178.
129. Cheng Y, Liu X, Yang J, Lin Y, Xu DZ, Lu Q, et al. MicroRNA-
145, a novel smooth muscle cell phenotypic marker and
modulator, controls vascular neointimal lesion formation.
Circ Res. Jul 17 2009;105(2):158e166.
130. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L,
Denecke B, et al. Delivery of microRNA-126 by apoptotic
bodies induces CXCL12-dependent vascular protection. Sci
Signal. Dec 8 2009;2(100):ra81.
131. Damas JK, Waehre T, Yndestad A, Ueland T, Muller F,
Eiken HG, et al. Stromal cell-derived factor-1alpha in unsta-
ble angina: potential antiinflammatory and matrix-stabilizing
effects. Circulation. Jul 2 2002;106(1):36e42.
132. Seeger FH, Rasper T, Koyanagi M, Fox H, Zeiher AM,
Dimmeler S. CXCR4 expression determines functional activity
of bone marrow-derived mononuclear cells for therapeutic
neovascularization in acute ischemia. Arteriosc Thromb Vasc
Biol. Nov 2009;29(11):1802e1809.
34 R.L. Neppl, D.-Z. Wang133. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, et al.
miR-126 regulates angiogenic signaling and vascular integrity.
Dev Cell. Aug 2008;15(2):272e284.
134. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA,
et al. The endothelial-specific microRNA miR-126 governs
vascular integrity and angiogenesis. Dev Cell. Aug 2008;15(2):
261e271.
135. Zhou J, Li YS, Nguyen P, Wang KC, Weiss A, Kuo YC, et al.
Regulation of vascular smooth muscle cell turnover by endo-
thelial cell-secreted microRNA-126: role of shear stress. Circ
Res. Jun 21 2013;113(1):40e51.
136. Katare R, Riu F, Mitchell K, Gubernator M, Campagnolo P,
Cui Y, et al. Transplantation of human pericyte progenitor
cells improves the repair of infarcted heart through activation
of an angiogenic program involving micro-RNA-132. Circ Res.
Sep 30 2011;109(8):894e906.
137. Klein ME, Lioy DT, Ma L, Impey S, Mandel G, Goodman RH.
Homeostatic regulation of MeCP2 expression by a CREB-
induced microRNA. Nat Neurosci. Dec 2007;10(12):
1513e1514.
138. Lagos D, Pollara G, Henderson S, Gratrix F, Fabani M, Milne RS,
et al. miR-132 regulates antiviral innate immunity through
suppression of the p300 transcriptional co-activator. Nat Cell
Biol. May 2010;12(5):513e519.
139. Anand S, Majeti BK, Acevedo LM, Murphy EA, Mukthavaram R,
Scheppke L, et al. MicroRNA-132-mediated loss of p120Ras-
GAP activates the endothelium to facilitate pathological
angiogenesis. Nat Med. Aug 2010;16(8):909e914.
140. Westenskow PD, Kurihara T, Aguilar E, Scheppke EL,
Moreno SK, Wittgrove C, et al. Ras pathway inhibition pre-
vents neovascularization by repressing endothelial cell
sprouting. J Clin Invest. Nov 1 2013;123(11):4900e4908.
141. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ,
Radziejewski C, et al. Angiopoietin-2, a natural antagonist for
Tie2 that disrupts in vivo angiogenesis. Sci New York, N.Y. Jul
4 1997;277(5322):55e60.
142. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S,
Thurston G, et al. Angiopoietin-2 sensitizes endothelial cells
to TNF-alpha and has a crucial role in the induction of
inflammation. Nat Med. Feb 2006;12(2):235e239.
143. Gale NW, Thurston G, Hackett SF, Renard R, Wang Q,
McClain J, et al. Angiopoietin-2 is required for postnatal
angiogenesis and lymphatic patterning, and only the latter
role is rescued by Angiopoietin-1. Dev Cell. Sep 2002;3(3):
411e423.
144. Nagy JA, Dvorak AM, Dvorak HF. Vascular hyperpermeability,
angiogenesis, and stroma generation. Cold Spring Harb Per-
spect Med. Feb 2012;2(2):a006544.
145. Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT,
Yeo TK, et al. Vascular permeability factor (VPF, VEGF) in
tumor biology. Cancer Metastasis Rev. Sep 1993;12(3e4):
303e324.
146. Lee CG, Link H, Baluk P, Homer RJ, Chapoval S, Bhandari V,
et al. Vascular endothelial growth factor (VEGF) induces
remodeling and enhances TH2-mediated sensitization and
inflammation in the lung. Nat Med. Oct 2004;10(10):
1095e1103.
147. Cursiefen C, Chen L, Borges LP, Jackson D, Cao J,
Radziejewski C, et al. VEGF-A stimulates lymphangiogenesis
and hemangiogenesis in inflammatory neovascularization via
macrophage recruitment. J Clin Invest. Apr 2004;113(7):
1040e1050.
148. Kim I, Moon SO, Park SK, Chae SW, Koh GY. Angiopoietin-1
reduces VEGF-stimulated leukocyte adhesion to endothelial
cells by reducing ICAM-1, VCAM-1, and E-selectin expression.
Circ Res. Sep 14 2001;89(6):477e479.
149. Yin KJ, Olsen K, Hamblin M, Zhang J, Schwendeman SP,
Chen YE. Vascular endothelial cell-specific microRNA-15ainhibits angiogenesis in hindlimb ischemia. J Biol Chem. Aug 3
2012;287(32):27055e27064.
150. Lei Z, Li B, Yang Z, Fang H, Zhang GM, Feng ZH, et al.
Regulation of HIF-1alpha and VEGF by miR-20b tunes tumor
cells to adapt to the alteration of oxygen concentration. PLoS
One. 2009;4(10):e7629.
151. Stahlhut C, Suarez Y, Lu J, Mishima Y, Giraldez AJ. miR-1 and
miR-206 regulate angiogenesis by modulating VegfA expres-
sion in zebrafish. Dev Camb Engl. Dec 1 2012;139(23):
4356e4364.
152. McArthur K, Feng B, Wu Y, Chen S, Chakrabarti S. MicroRNA-
200b regulates vascular endothelial growth factor-mediated
alterations in diabetic retinopathy. Diabetes. Apr 2011;60(4):
1314e1323.
153. Long J, Wang Y, Wang W, Chang BH, Danesh FR. Identification
of microRNA-93 as a novel regulator of vascular endothelial
growth factor in hyperglycemic conditions. J Biol Chem. Jul
23 2010;285(30):23457e23465.
154. Hassel D, Cheng P, White MP, Ivey KN, Kroll J, Augustin HG,
et al. MicroRNA-10 regulates the angiogenic behavior of
zebrafish and human endothelial cells by promoting vascular
endothelial growth factor signaling. Circ Res. Nov 9 2012;
111(11):1421e1433.
155. Zhuang G, Wu X, Jiang Z, Kasman I, Yao J, Guan Y, et al.
Tumour-secreted miR-9 promotes endothelial cell migration
and angiogenesis by activating the JAK-STAT pathway. EMBO
J. Aug 29 2012;31(17):3513e3523.
156. Wurdinger T, Tannous BA, Saydam O, Skog J, Grau S,
Soutschek J, et al. miR-296 regulates growth factor receptor
overexpression in angiogenic endothelial cells. Cancer Cell.
Nov 4 2008;14(5):382e393.
157. Kuhnert F, Mancuso MR, Hampton J, Stankunas K, Asano T,
Chen CZ, et al. Attribution of vascular phenotypes of the
murine Egfl7 locus to the microRNA miR-126. Dev Camb Engl.
Dec 2008;135(24):3989e3993.
158. Small EM, O’Rourke JR, Moresi V, Sutherland LB, McAnally J,
Gerard RD, et al. Regulation of PI3-kinase/Akt signaling by
muscle-enriched microRNA-486. Proc Natl Acad Sci U S A. Mar
2 2010;107(9):4218e4223.
159. Agudo J, Ruzo A, Tung N, Salmon H, Leboeuf M, Hashimoto D,
et al. The miR-126-VEGFR2 axis controls the innate response
to pathogen-associated nucleic acids. Nat Immunol. Jan 2014;
15(1):54e62.
160. Nazari-Jahantigh M, Wei Y, Noels H, Akhtar S, Zhou Z,
Koenen RR, et al. MicroRNA-155 promotes atherosclerosis by
repressing Bcl6 in macrophages. J Clin Invest. Nov 1 2012;
122(11):4190e4202.
161. Wei Y, Nazari-Jahantigh M, Chan L, Zhu M, Heyll K, Corbalan-
Campos J, et al. The microRNA-342-5p fosters inflammatory
macrophage activation through an Akt1- and microRNA-155-
dependent pathway during atherosclerosis. Circulation. Apr
16 2013;127(15):1609e1619.
162. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-
dependent induction of microRNA miR-146, an inhibitor tar-
geted to signaling proteins of innate immune responses. Proc
Natl Acad Sci U S A. Aug 15 2006;103(33):12481e12486.
163. Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC,
et al. Toll-like receptor-4 is expressed by macrophages in
murine and human lipid-rich atherosclerotic plaques and
upregulated by oxidized LDL. Circulation. Dec 18 2001;
104(25):3103e3108.
164. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, Martin C,
O’Leary JJ, Ruan Q, et al. Negative regulation of TLR4 via
targeting of the proinflammatory tumor suppressor PDCD4 by
the microRNA miR-21. Nat Immunol. Feb 2010;11(2):141e147.
165. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH,
Colburn NH, Post S, et al. MicroRNA-21 (miR-21) post-tran-
scriptionally downregulates tumor suppressor Pdcd4 and
Roles of microRNAs in cardiovascular homeostasis and disease 35stimulates invasion, intravasation and metastasis in colo-
rectal cancer. Oncogene. Apr 3 2008;27(15):2128e2136.
166. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M,
Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an
important functional target of the microRNA miR-21 in breast
cancer cells. The Journal of biological chemistry. Jan 11 2008;
283(2):1026e1033.
167. Ji R, Cheng Y, Yue J, Yang J, Liu X, Chen H, et al.
MicroRNA expression signature and antisense-mediated
depletion reveal an essential role of MicroRNA in vascular
neointimal lesion formation. Circ Res. Jun 8 2007;100(11):
1579e1588.
168. Liu X, Cheng Y, Zhang S, Lin Y, Yang J, Zhang C. A necessary
role of miR-221 and miR-222 in vascular smooth muscle cell
proliferation and neointimal hyperplasia. Circ Res. Feb 27
2009;104(4):476e487.
169. Du Y, Gao C, Liu Z, Wang L, Liu B, He F, et al. Upregulation of
a disintegrin and metalloproteinase with thrombospondin
motifs-7 by miR-29 repression mediates vascular smooth
muscle calcification. Arteriosc Thromb Vasc Biol. Nov 2012;
32(11):2580e2588.
170. Reilly MP, Li M, He J, Ferguson JF, Stylianou IM, Mehta NN,
et al. Identification of ADAMTS7 as a novel locus for coronary
atherosclerosis and association of ABO with myocardial
infarction in the presence of coronary atherosclerosis: two
genome-wide association studies. Lancet. Jan 29 2011;
377(9763):383e392.
171. van Setten J, Isgum I, Smolonska J, Ripke S, de Jong PA,
Oudkerk M, et al. Genome-wide association study of coronary
and aortic calcification implicates risk loci for coronary artery
disease and myocardial infarction. Atherosclerosis. Jun 2013;
228(2):400e405.
172. Wang L, Zheng J, Bai X, Liu B, Liu CJ, Xu Q, et al. ADAMTS-7
mediates vascular smooth muscle cell migration and neo-
intima formation in balloon-injured rat arteries. Circ Res. Mar
13 2009;104(5):688e698.
173. Rong JX, Li J, Reis ED, Choudhury RP, Dansky HM, Elmalem VI,
et al. Elevating high-density lipoprotein cholesterol in apoli-
poprotein E-deficient mice remodels advanced atheroscle-
rotic lesions by decreasing macrophage and increasing smooth
muscle cell content. Circulation. Nov 13 2001;104(20):
2447e2452.
174. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ,
Yasin M, et al. Effect of recombinant ApoA-I Milano on coro-
nary atherosclerosis in patients with acute coronary syn-
dromes: a randomized controlled trial. JAMA. Nov 5 2003;
290(17):2292e2300.
175. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD,
Remaley AT. MicroRNAs are transported in plasma and deliv-
ered to recipient cells by high-density lipoproteins. Nat Cell
Biol. Apr 2011;13(4):423e433.
176. Tabet F, Vickers KC, Cuesta Torres LF, Wiese CB, Shoucri BM,
Lambert G, et al. HDL-transferred microRNA-223 regulates
ICAM-1 expression in endothelial cells. Nat Commun. 2014;5:
3292.
177. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate he-
matopoietic lineage differentiation. Sci New York, N.Y. Jan 2
2004;303(5654):83e86.
178. Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE,
Parathath S, et al. Antagonism of miR-33 in mice promotes
reverse cholesterol transport and regression of atheroscle-
rosis. J Clin Invest. Jul 2011;121(7):2921e2931.
179. Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML,
Tamehiro N, et al. MiR-33 contributes to the regulation of
cholesterol homeostasis. Sci New York, N.Y. Jun 18 2010;
328(5985):1570e1573.
180. Rayner KJ, Esau CC, Hussain FN, McDaniel AL, Marshall SM,
van Gils JM, et al. Inhibition of miR-33a/b in non-humanprimates raises plasma HDL and lowers VLDL triglycerides.
Nature. Oct 20 2011;478(7369):404e407.
181. Ramirez CM, Rotllan N, Vlassov AV, Davalos A, Li M,
Goedeke L, et al. Control of cholesterol metabolism and
plasma high-density lipoprotein levels by microRNA-144. Circ
Res. Jun 7 2013;112(12):1592e1601.
182. Soh J, Iqbal J, Queiroz J, Fernandez-Hernando C, Hussain MM.
MicroRNA-30c reduces hyperlipidemia and atherosclerosis in
mice by decreasing lipid synthesis and lipoprotein secretion.
Nat Med. Jul 2013;19(7):892e900.
183. Davalos A, Goedeke L, Smibert P, Ramirez CM, Warrier NP,
Andreo U, et al. miR-33a/b contribute to the regulation of
fatty acid metabolism and insulin signaling. Proc Natl Acad Sci
U S A. May 31 2011;108(22):9232e9237.
184. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, et al.
miR-122 regulation of lipid metabolism revealed by in vivo
antisense targeting. Cell Metab. Feb 2006;3(2):87e98.
185. Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H, et al.
Essential metabolic, anti-inflammatory, and anti-tumorigenic
functions of miR-122 in liver. J Clin Invest. Aug 1 2012;122(8):
2871e2883.
186. Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, et al.
MicroRNA-122 plays a critical role in liver homeostasis and
hepatocarcinogenesis. J Clin Invest. Aug 1 2012;122(8):
2884e2897.
187. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA,
Izzo Jr JL, et al. Seventh report of the Joint National Com-
mittee on Prevention, detection, Evaluation, and treatment
of high blood pressure. Hypertension. Dec 2003;42(6):
1206e1252.
188. Guyton AC. Blood pressure controlespecial role of the kidneys
and body fluids. Sci New York, N.Y. Jun 28 1991;252(5014):
1813e1816.
189. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of
human hypertension. Cell. Feb 23 2001;104(4):545e556.
190. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA,
Bevan JA, et al. Hypertension in mice lacking the gene for
endothelial nitric oxide synthase. Nature. Sep 21 1995;
377(6546):239e242.
191. Tang KM, Wang GR, Lu P, Karas RH, Aronovitz M, Heximer SP,
et al. Regulator of G-protein signaling-2 mediates vascular
smooth muscle relaxation and blood pressure. Nat Med. Dec
2003;9(12):1506e1512.
192. Brenner R, Perez GJ, Bonev AD, Eckman DM, Kosek JC,
Wiler SW, et al. Vasoregulation by the beta1 subunit of the
calcium-activated potassium channel. Nature. Oct 19 2000;
407(6806):870e876.
193. Zhu Y, Bian Z, Lu P, Karas RH, Bao L, Cox D, et al. Abnormal
vascular function and hypertension in mice deficient in es-
trogen receptor beta. Sci New York, N.Y. Jan 18 2002;
295(5554):505e508.
194. Michael SK, Surks HK, Wang Y, Zhu Y, Blanton R, Jamnongjit M,
et al. High blood pressure arising from a defect in vascular
function. Proc Natl Acad Sci U S A. May 6 2008;105(18):
6702e6707.
195. Mehta PK, Griendling KK. Angiotensin II cell signaling: physi-
ological and pathological effects in the cardiovascular sys-
tem. Am J Physiol. Jan 2007;292(1):C82eC97.
196. Tuder RM, Marecki JC, Richter A, Fijalkowska I, Flores S. Pa-
thology of pulmonary hypertension. Clin Chest Med. Mar
2007;28(1):23e42.
197. Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F.
Mechanisms of disease: pulmonary arterial hypertension. Nat
Rev Cardiol. Aug 2011;8(8):443e455.
198. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D,
et al. Normalization of the vasculature for treatment of
cancer and other diseases. Physiol Rev. Jul 2011;91(3):
1071e1121.
36 R.L. Neppl, D.-Z. Wang199. Aird WC. Endothelial cell heterogeneity. Cold Spring Harb
Perspect Med. Jan 2012;2(1):a006429.
200. Schober A. Chemokines in vascular dysfunction and remod-
eling. Arteriosc Thromb Vasc biology. Nov 2008;28(11):
1950e1959.
201. Heeneman S, Sluimer JC, Daemen MJ. Angiotensin-converting
enzyme and vascular remodeling. Circ Res. Aug 31 2007;
101(5):441e454.
202. Eddahibi S, Guignabert C, Barlier-Mur AM, Dewachter L,
Fadel E, Dartevelle P, et al. Cross talk between endothelial
and smooth muscle cells in pulmonary hypertension: critical
role for serotonin-induced smooth muscle hyperplasia. Cir-
culation. Apr 18 2006;113(15):1857e1864.
203. Izikki M, Guignabert C, Fadel E, Humbert M, Tu L, Zadigue P,
et al. Endothelial-derived FGF2 contributes to the progression
of pulmonary hypertension in humans and rodents. J Clin
Invest. Mar 2009;119(3):512e523.
204. Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC,
Grimminger F, et al. Inflammation, growth factors, and pul-
monary vascular remodeling. J Am Coll Cardiol. Jun 30 2009;
54(1 Suppl):S10eS19.
205. Sheikh AY, Chun HJ, Glassford AJ, Kundu RK, Kutschka I,
Ardigo D, et al. In vivo genetic profiling and cellular locali-
zation of apelin reveals a hypoxia-sensitive, endothelial-
centered pathway activated in ischemic heart failure. Am J
Physiol Heart Circ Physiol. Jan 2008;294(1):H88eH98.
206. Ishida J, Hashimoto T, Hashimoto Y, Nishiwaki S, Iguchi T,
Harada S, et al. Regulatory roles for APJ, a seven-trans-
membrane receptor related to angiotensin-type 1 receptor in
blood pressure in vivo. J Biol Chem. Jun 18 2004;279(25):
26274e26279.
207. Zhong JC, Yu XY, Huang Y, Yung LM, Lau CW, Lin SG. Apelin
modulates aortic vascular tone via endothelial nitric oxide
synthase phosphorylation pathway in diabetic mice. Car-
diovasc Res. Jun 1 2007;74(3):388e395.
208. Chandra SM, Razavi H, Kim J, Agrawal R, Kundu RK, de Jesus
Perez V, et al. Disruption of the apelin-APJ system worsens
hypoxia-induced pulmonary hypertension. Arteriosc Thromb
Vasc Biol. Apr 2011;31(4):814e820.
209. Alastalo TP, Li M, Perez Vde J, Pham D, Sawada H, Wang JK,
et al. Disruption of PPARgamma/beta-catenin-mediated
regulation of apelin impairs BMP-induced mouse and human
pulmonary arterial EC survival. J Clin Invest. Sep 2011;121(9):
3735e3746.
210. Kim J, Kang Y, Kojima Y, Lighthouse JK, Hu X, Aldred MA,
et al. An endothelial apelin-FGF link mediated by miR-424 and
miR-503 is disrupted in pulmonary arterial hypertension. Nat
Med. Jan 2013;19(1):74e82.
211. Sun HX, Zeng DY, Li RT, Pang RP, Yang H, Hu YL, et al.
Essential role of microRNA-155 in regulating endothelium-
dependent vasorelaxation by targeting endothelial nitric
oxide synthase. Hypertension. Dec 2012;60(6):1407e1414.
212. Crowley SD, Gurley SB, Herrera MJ, Ruiz P, Griffiths R,
Kumar AP, et al. Angiotensin II causes hypertension and car-
diac hypertrophy through its receptors in the kidney. Proc
Natl Acad Sci U S A. Nov 21 2006;103(47):17985e17990.
213. Spiering W, Kroon AA, Fuss-Lejeune MM, Daemen MJ, de
Leeuw PW. Angiotensin II sensitivity is associated with the
angiotensin II type 1 receptor A(1166)C polymorphism in
essential hypertensives on a high sodium diet. Hypertension.
Sep 2000;36(3):411e416.
214. van Geel PP, Pinto YM, Voors AA, Buikema H, Oosterga M,
Crijns HJ, et al. Angiotensin II type 1 receptor A1166C gene
polymorphism is associated with an increased response to
angiotensin II in human arteries. Hypertension. Mar 2000;
35(3):717e721.
215. Yang Z, Venardos K, Jones E, Morris BJ, Chin-Dusting J,
Kaye DM. Identification of a novel polymorphism in the 3’UTRof the L-arginine transporter gene SLC7A1: contribution to
hypertension and endothelial dysfunction. Circulation. Mar 13
2007;115(10):1269e1274.
216. Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA,
et al. miR-122, a mammalian liver-specific microRNA, is pro-
cessed from hcr mRNA and may downregulate the high affinity
cationic amino acid transporter CAT-1. RNA Biol. Jul 2004;
1(2):106e113.
217. Bhattacharyya SN, Habermacher R, Martine U, Closs EI,
Filipowicz W. Relief of microRNA-mediated translational
repression in human cells subjected to stress. Cell. Jun 16
2006;125(6):1111e1124.
218. Wei Z, Biswas N, Wang L, Courel M, Zhang K, Soler-Jover A,
et al. A common genetic variant in the 3’-UTR of vacuolar H+-
ATPase ATP6V0A1 creates a micro-RNA motif to alter chro-
mogranin A processing and hypertension risk. Circ Cardiovasc
Genet. Aug 1 2011;4(4):381e389.
219. Mahata SK, O’Connor DT, Mahata M, Yoo SH, Taupenot L,
Wu H, et al. Novel autocrine feedback control of catechol-
amine release. A discrete chromogranin a fragment is a
noncompetitive nicotinic cholinergic antagonist. J Clin Invest.
Sep 15 1997;100(6):1623e1633.
220. Taupenot L, Harper KL, O’Connor DT. The chromogranin-
secretogranin family. N. Engl J Med. Mar 20 2003;348(12):
1134e1149.
221. O’Connor DT, Zhu G, Rao F, Taupenot L, Fung MM, Das M,
et al. Heritability and genome-wide linkage in US and
australian twins identify novel genomic regions controlling
chromogranin a: implications for secretion and blood pres-
sure. Circulation. Jul 15 2008;118(3):247e257.
222. Arora P, Wu C, Khan AM, Bloch DB, Davis-Dusenbery BN,
Ghorbani A, et al. Atrial natriuretic peptide is negatively
regulated by microRNA-425. J Clin Invest. Aug 1 2013;123(8):
3378e3382.
223. Nossent AY, Hansen JL, Doggen C, Quax PH, Sheikh SP,
Rosendaal FR. SNPs in microRNA binding sites in 3’-UTRs of
RAAS genes influence arterial blood pressure and risk of
myocardial infarction. Am J Hypertens. Sep 2011;24(9):
999e1006.
224. Ellis EF, Oelz O, Roberts 2nd LJ, Payne NA, Sweetman BJ,
Nies AS, et al. Coronary arterial smooth muscle contraction by
a substance released from platelets: evidence that it is
thromboxane A2. Sci New York, N.Y. Sep 17 1976;193(4258):
1135e1137.
225. Buzzard CJ, Pfister SL, Campbell WB. Endothelium-dependent
contractions in rabbit pulmonary artery are mediated by
thromboxane A2. Circ Res. May 1993;72(5):1023e1034.
226. Neppl RL, Lubomirov LT, Momotani K, Pfitzer G, Eto M,
Somlyo AV. Thromboxane A2-induced Bi-directional regula-
tion of cerebral arterial tone. J Biol Chem. Mar 6 2009;
284(10):6348e6360.
227. Semenza GL. HIF-1, O(2), and the 3 PHDs: how animal cells
signal hypoxia to the nucleus. Cell. Oct 5 2001;107(1):1e3.
228. Ghosh G, Subramanian IV, Adhikari N, Zhang X, Joshi HP,
Basi D, et al. Hypoxia-induced microRNA-424 expression in
human endothelial cells regulates HIF-alpha isoforms and
promotes angiogenesis. J Clin Invest. Nov 2010;120(11):
4141e4154.
229. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H,
Agosto-Perez FJ, et al. A microRNA signature of hypoxia. Mol
Cell Biol. Mar 2007;27(5):1859e1867.
230. Kelly TJ, Souza AL, Clish CB, Puigserver P. A hypoxia-induced
positive feedback loop promotes hypoxia-inducible factor
1alpha stability through miR-210 suppression of glycerol-3-
phosphate dehydrogenase 1-like. Mol Cell Biol. Jul 2011;
31(13):2696e2706.
231. Fasanaro P, D’Alessandra Y, Di Stefano V, Melchionna R,
Romani S, Pompilio G, et al. MicroRNA-210 modulates
Roles of microRNAs in cardiovascular homeostasis and disease 37endothelial cell response to hypoxia and inhibits the receptor
tyrosine kinase ligand Ephrin-A3. J Biol Chem. Jun 6 2008;
283(23):15878e15883.
232. Hu S, Huang M, Li Z, Jia F, Ghosh Z, Lijkwan MA, et al.
MicroRNA-210 as a novel therapy for treatment of ischemic
heart disease. Circulation. Sep 14 2010;122(11 Suppl):
S124eS131.
233. Crosby ME, Kulshreshtha R, Ivan M, Glazer PM. MicroRNA
regulation of DNA repair gene expression in hypoxic stress.
Cancer Res. Feb 1 2009;69(3):1221e1229.
234. Giannakakis A, Sandaltzopoulos R, Greshock J, Liang S,
Huang J, Hasegawa K, et al. miR-210 links hypoxia with cell
cycle regulation and is deleted in human epithelial ovarian
cancer. Cancer Biol Ther. Feb 2008;7(2):255e264.
235. Kim HW, Haider HK, Jiang S, Ashraf M. Ischemic pre-
conditioning augments survival of stem cells via miR-210
expression by targeting caspase-8-associated protein 2. J Biol
Chem. Nov 27 2009;284(48):33161e33168.
236. Chan SY, Zhang YY, Hemann C, Mahoney CE, Zweier JL,
Loscalzo J. MicroRNA-210 controls mitochondrial metabolism
during hypoxia by repressing the iron-sulfur cluster assembly
proteins ISCU1/2. Cell Metab. Oct 2009;10(4):273e284.
237. Semenza GL. Oxygen-dependent regulation of mitochondrial
respiration by hypoxia-inducible factor 1. Biochem J. Jul 1
2007;405(1):1e9.
238. Semenza GL. Hypoxia-inducible factors in physiology and
medicine. Cell. Feb 3 2012;148(3):399e408.
239. Guo L, Qiu Z, Wei L, Yu X, Gao X, Jiang S, et al. The microRNA-
328 regulates hypoxic pulmonary hypertension by targeting at
insulin growth factor 1 receptor and L-type calcium channel-
alpha1C. Hypertension. May 2012;59(5):1006e1013.
240. Somlyo AP, Somlyo AV. Signal transduction and regulation in
smooth muscle. Nature. Nov 17 1994;372(6503):231e236.
241. Bers DM. Cardiac excitation-contraction coupling. Nature. Jan
10 2002;415(6868):198e205.
242. Hofmann F, Flockerzi V, Kahl S, Wegener JW. L-type CaV1.2
calcium channels: from in vitro findings to in vivo function.
Physiol Rev. Jan 2014;94(1):303e326.
243. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice
carrying null mutations of the genes encoding insulin-like
growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell.
Oct 8 1993;75(1):59e72.
244. Wu C, So J, Davis-Dusenbery BN, Qi HH, Bloch DB, Shi Y, et al.
Hypoxia potentiates microRNA-mediated gene silencing
through posttranslational modification of Argonaute2. Mol
Cell Biol. Dec 2011;31(23):4760e4774.
245. Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A,
Webster L, et al. The nuclear factor of activated T cells in
pulmonary arterial hypertension can be therapeutically tar-
geted. Proc Natl Acad Sci U S A. Jul 3 2007;104(27):
11418e11423.
246. Jasmin JF, Mercier I, Dupuis J, Tanowitz HB, Lisanti MP. Short-
term administration of a cell-permeable caveolin-1 peptide
prevents the development of monocrotaline-induced pulmo-
nary hypertension and right ventricular hypertrophy. Circu-
lation. Aug 29 2006;114(9):912e920.
247. Paulin R, Courboulin A, Meloche J, Mainguy V, Dumas de la
Roque E, Saksouk N, et al. Signal transducers and activators of
transcription-3/pim1 axis plays a critical role in the patho-
genesis of human pulmonary arterial hypertension. Circula-
tion. Mar 22 2011;123(11):1205e1215.
248. Lee C, Mitsialis SA, Aslam M, Vitali SH, Vergadi E,
Konstantinou G, et al. Exosomes mediate the cytoprotective
action of mesenchymal stromal cells on hypoxia-induced
pulmonary hypertension. Circulation. Nov 27 2012;126(22):
2601e2611.
249. Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R,
et al. miR-328 functions as an RNA decoy to modulate hnRNPE2 regulation of mRNA translation in leukemic blasts. Cell.
Mar 5 2010;140(5):652e665.
250. Meng F, Henson R, Wehbe-Janek H, Smith H, Ueno Y, Patel T.
The MicroRNA let-7a modulates interleukin-6-dependent
STAT-3 survival signaling in malignant human cholangiocytes.
J Biol Chem. Mar 16 2007;282(11):8256e8264.
251. Curtale G, Mirolo M, Renzi TA, Rossato M, Bazzoni F, Locati M.
Negative regulation of Toll-like receptor 4 signaling by IL-10-
dependent microRNA-146b. Proc Natl Acad Sci U S A. Jul 9
2013;110(28):11499e11504.
252. Mycko MP, Cichalewska M, Machlanska A, Cwiklinska H,
Mariasiewicz M, Selmaj KW. MicroRNA-301a regulation of a T-
helper 17 immune response controls autoimmune demyelin-
ation. Proc Natl Acad Sci U S A. May 15 2012;109(20):
E1248eE1257.
253. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3
activation of miR-21 and miR-181b-1 via PTEN and CYLD are
part of the epigenetic switch linking inflammation to cancer.
Mol Cell. Aug 27 2010;39(4):493e506.
254. Adams Jr HP, del Zoppo G, Alberts MJ, Bhatt DL, Brass L,
Furlan A, et al. Guidelines for the early management of adults
with ischemic stroke: a guideline from the American Heart
Association/American Stroke Association Stroke Council, Clin-
ical Cardiology Council, Cardiovascular Radiology and Inter-
vention Council, and the Atherosclerotic Peripheral Vascular
Disease and Quality of Care Outcomes in Research Interdisci-
plinary Working Groups: the American Academy of Neurology
affirms the value of this guideline as an educational tool for
neurologists. Stroke; J Cereb Circ. May 2007;38(5):1655e1711.
255. Cahill J, Calvert JW, Zhang JH. Mechanisms of early brain
injury after subarachnoid hemorrhage. J Cereb Blood Flow
Metab: Off J Int Soc Cereb Blood Flow Metab. Nov 2006;
26(11):1341e1353.
256. Bardutzky J, Schwab S. Antiedema therapy in ischemic stroke.
Stroke; J Cereb Circ. Nov 2007;38(11):3084e3094.
257. Jeyaseelan K, Lim KY, Armugam A. MicroRNA expression in the
blood and brain of rats subjected to transient focal ischemia
by middle cerebral artery occlusion. Stroke; J Cereb Circ. Mar
2008;39(3):959e966.
258. Toung TJ, Traystman RJ, Hurn PD. Estrogen-mediated neu-
roprotection after experimental stroke in male rats. Stroke; J
Cereb Circ. Aug 1998;29(8):1666e1670.
259. Yang SH, Shi J, Day AL, Simpkins JW. Estradiol exerts neuro-
protective effects when administered after ischemic insult.
Stroke; J Cereb Circ. Mar 2000;31(3):745e749. discussion
749e750.
260. Hurn PD, Macrae IM. Estrogen as a neuroprotectant in stroke.
J Cereb blood Flow Metab: Off J Int Soc Cereb Blood Flow
Metabolism. Apr 2000;20(4):631e652.
261. Siegel C, Li J, Liu F, Benashski SE, McCullough LD. miR-23a
regulation of X-linked inhibitor of apoptosis (XIAP) contributes
to sex differences in the response to cerebral ischemia. Proc
Natl Acad Sci U S A. Jul 12 2011;108(28):11662e11667.
262. Frigeri A, Gropper MA, Turck CW, Verkman AS. Immunolocal-
ization of the mercurial-insensitive water channel and glyc-
erol intrinsic protein in epithelial cell plasma membranes.
Proc Natl Acad Sci U S A. May 9 1995;92(10):4328e4331.
263. Nielsen S, Nagelhus EA, Amiry-Moghaddam M, Bourque C,
Agre P, Ottersen OP. Specialized membrane domains for
water transport in glial cells: high-resolution immunogold
cytochemistry of aquaporin-4 in rat brain. J Neurosci: Off J
Soc Neurosci. Jan 1 1997;17(1):171e180.
264. Manley GT, Fujimura M, Ma T, Noshita N, Filiz F, Bollen AW,
et al. Aquaporin-4 deletion in mice reduces brain edema after
acute water intoxication and ischemic stroke. Nat Med. Feb
2000;6(2):159e163.
265. Sepramaniam S, Armugam A, Lim KY, Karolina DS,
Swaminathan P, Tan JR, et al. MicroRNA 320a functions as a
38 R.L. Neppl, D.-Z. Wangnovel endogenous modulator of aquaporins 1 and 4 as well as
a potential therapeutic target in cerebral ischemia. J Biol
Chem. Sep 17 2010;285(38):29223e29230.
266. Ren XP, Wu J, Wang X, Sartor MA, Qian J, Jones K, et al.
MicroRNA-320 is involved in the regulation of cardiac ische-
mia/reperfusion injury by targeting heat-shock protein 20.
Circulation. May 5 2009;119(17):2357e2366.
267. Quraishe S, Asuni A, Boelens WC, O’Connor V, Wyttenbach A.
Expression of the small heat shock protein family in the
mouse CNS: differential anatomical and biochemical
compartmentalization. Neuroscience. May 2 2008;153(2):
483e491.
268. Bronisz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO,
Mathsyaraja H, et al. Reprogramming of the tumour micro-
environment by stromal PTEN-regulated miR-320. Nat Cell
Biol. Feb 2012;14(2):159e167.
269. Wu YY, Chen YL, Jao YC, Hsieh IS, Chang KC, Hong TM. miR-
320 regulates tumor angiogenesis driven by vascular endo-
thelial cells in oral cancer by silencing neuropilin 1. Angio-
genesis. Jan 2014;17(1):247e260.
270. Tang H, Lee M, Sharpe O, Salamone L, Noonan EJ, Hoang CD,
et al. Oxidative stress-responsive microRNA-320 regulates
glycolysis in diverse biological systems. FASEB journal. Off
Publ Fed Am Soc Exp Biol. Nov 2012;26(11):4710e4721.
271. Kim DH, Saetrom P, Snove Jr O, Rossi JJ. MicroRNA-directed
transcriptional gene silencing in mammalian cells. Proc Natl
Acad Sci U S A. Oct 21 2008;105(42):16230e16235.
272. Lee JM, Zipfel GJ, Choi DW. The changing landscape of
ischaemic brain injury mechanisms. Nature. Jun 24 1999;
399(6738 Suppl):A7eA14.
273. Edbauer D, Neilson JR, Foster KA, Wang CF, Seeburg DP,
Batterton MN, et al. Regulation of synaptic structure and
function by FMRP-associated microRNAs miR-125b and miR-
132. Neuron. Feb 11 2010;65(3):373e384.
274. Saba R, Storchel PH, Aksoy-Aksel A, Kepura F, Lippi G,
Plant TD, et al. Dopamine-regulated microRNA MiR-181a
controls GluA2 surface expression in hippocampal neurons.
Mol Cell Biol. Feb 2012;32(3):619e632.
275. Harraz MM, Eacker SM, Wang X, Dawson TM, Dawson VL.
MicroRNA-223 is neuroprotective by targeting glutamate re-
ceptors. Proc Natl Acad Sci U S A. Nov 13 2012;109(46):
18962e18967.
276. Alberti KG, Zimmet P, Shaw J. The metabolic syndromeea
new worldwide definition. Lancet. Sep 24-30 2005;366(9491):
1059e1062.
277. Beltran-Sanchez H, Harhay MO, Harhay MM, McElligott S.
Prevalence and trends of metabolic syndrome in the adult
U.S. population, 1999-2010. J Am Coll Cardiol. Aug 20 2013;
62(8):697e703.
278. Ervin RB. Preval metabolic syndrome among adults 20 years
age over, by Sex age, race Ethn body mass index: United
States, 2003-2006. Natl Health Stat Rep. May 5 2009;(13):
1e7.
279. Herder C, Karakas M, Koenig W. Biomarkers for the prediction
of type 2 diabetes and cardiovascular disease. Clin Pharmacol
Ther. Jul 2011;90(1):52e66.
280. Raitoharju E, Seppala I, Oksala N, Lyytikainen LP, Raitakari O,
Viikari J, et al. Blood microRNA profile associates with the
levels of serum lipids and metabolites associated with glucose
metabolism and insulin resistance and pinpoints pathways
underlying metabolic syndrome. Mol Cell Endocrinol. Apr 28
2014;391(1e2):41e49.
281. Hulsmans M, Sinnaeve P, Van der Schueren B, Mathieu C,
Janssens S, Holvoet P. Decreased miR-181a expression in
monocytes of obese patients is associated with the occur-
rence of metabolic syndrome and coronary artery disease. J
Clin Endocrinol Metab. Jul 2012;97(7):E1213eE1218.282. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. Loss of
the cylindromatosis tumour suppressor inhibits apoptosis by
activating NF-kappaB. Nature. Aug 14 2003;424(6950):
797e801.
283. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H,
Ashworth A, Mosialos G. CYLD is a deubiquitinating enzyme
that negatively regulates NF-kappaB activation by
TNFR family members. Nature. Aug 14 2003;424(6950):
793e796.
284. Puigserver P, Spiegelman BM. Peroxisome proliferator-acti-
vated receptor-gamma coactivator 1 alpha (PGC-1 alpha):
transcriptional coactivator and metabolic regulator. Endocr
Rev. Feb 2003;24(1):78e90.
285. Rosen ED, Spiegelman BM. What we talk about when we talk
about fat. Cell. Jan 16 2014;156(1e2):20e44.
286. Carrer M, Liu N, Grueter CE, Williams AH, Frisard MI,
Hulver MW, et al. Control of mitochondrial metabolism and
systemic energy homeostasis by microRNAs 378 and 378*. Proc
Natl Acad Sci U S A. Sep 18 2012;109(38):15330e15335.
287. Grueter CE, van Rooij E, Johnson BA, Deleon SM,
Sutherland LB, Qi X, et al. A cardiac MicroRNA governs sys-
temic Energy homeostasis by regulation of MED13. Cell. Apr
27 2012;149(3):671e683.
288. Spinazzola A, Viscomi C, Fernandez-Vizarra E, Carrara F,
D’Adamo P, Calvo S, et al. MPV17 encodes an inner mito-
chondrial membrane protein and is mutated in infantile he-
patic mitochondrial DNA depletion. Nat Genet. May 2006;
38(5):570e575.
289. Krick S, Shi S, Ju W, Faul C, Tsai SY, Mundel P, et al. Mpv17l
protects against mitochondrial oxidative stress and apoptosis
by activation of Omi/HtrA2 protease. Proc Natl Acad Sci U S A.
Sep 16 2008;105(37):14106e14111.
290. Zhuang G, Meng C, Guo X, Cheruku PS, Shi L, Xu H, et al. A
novel regulator of macrophage activation: miR-223 in obesity-
associated adipose tissue inflammation. Circulation. Jun 12
2012;125(23):2892e2903.
291. Lee EK, Lee MJ, Abdelmohsen K, Kim W, Kim MM, Srikantan S,
et al. miR-130 suppresses adipogenesis by inhibiting peroxi-
some proliferator-activated receptor gamma expression. Mol
Cell Biol. Feb 2011;31(4):626e638.
292. Kim C, Lee H, Cho YM, Kwon OJ, Kim W, Lee EK. TNFalpha-
induced miR-130 resulted in adipocyte dysfunction during
obesity-related inflammation. FEBS Lett. Nov 29 2013;
587(23):3853e3858.
293. Trajkovski M, Hausser J, Soutschek J, Bhat B, Akin A,
Zavolan M, et al. MicroRNAs 103 and 107 regulate insulin
sensitivity. Nature. Jun 30 2011;474(7353):649e653.
294. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X,
Macdonald PE, et al. A pancreatic islet-specific microRNA
regulates insulin secretion. Nature. Nov 11 2004;432(7014):
226e230.
295. Sen S, Kundu G, Mekhail N, Castel J, Misono K, Healy B.
Myotrophin: purification of a novel peptide from spontane-
ously hypertensive rat heart that influences myocardial
growth. J Biol Chem. Sep 25 1990;265(27):16635e16643.
296. Sarkar S, Leaman DW, Gupta S, Sil P, Young D, Morehead A,
et al. Cardiac overexpression of myotrophin triggers
myocardial hypertrophy and heart failure in transgenic mice.
J Biol Chem. May 7 2004;279(19):20422e20434.
297. Antonin W, Riedel D, von Mollard GF. The SNARE Vti1a-beta is
localized to small synaptic vesicles and participates in a novel
SNARE complex. J Neurosci: Off J Soc Neurosci. Aug 1 2000;
20(15):5724e5732.
298. Poy MN, Hausser J, Trajkovski M, Braun M, Collins S,
Rorsman P, et al. miR-375 maintains normal pancreatic alpha-
and beta-cell mass. Proc Natl Acad Sci U S A. Apr 7 2009;
106(14):5813e5818.
Roles of microRNAs in cardiovascular homeostasis and disease 39299. Xu G, Chen J, Jing G, Shalev A. Thioredoxin-interacting pro-
tein regulates insulin transcription through microRNA-204.
Nat Med. Sep 2013;19(9):1141e1146.
300. Shao S, Fang Z, Yu X, Zhang M. Transcription factors involved
in glucose-stimulated insulin secretion of pancreatic beta
cells. Biochem Biophys Res Commun. Jul 10 2009;384(4):
401e404.
301. Ruan Q, Wang T, Kameswaran V, Wei Q, Johnson DS,
Matschinsky F, et al. The microRNA-21-PDCD4 axis prevents
type 1 diabetes by blocking pancreatic beta cell death. Proc
Natl Acad Sci U S A. Jul 19 2011;108(29):12030e12035.302. Jordan SD, Kruger M, Willmes DM, Redemann N,
Wunderlich FT, Bronneke HS, et al. Obesity-induced over-
expression of miRNA-143 inhibits insulin-stimulated AKT
activation and impairs glucose metabolism. Nat Cell Biol. Apr
2011;13(4):434e446.
303. Vetere A, Choudhary A, Burns SM, Wagner BK. Targeting the
pancreatic beta-cell to treat diabetes. Nat Rev Drug Discov.
Apr 2014;13(4):278e289.
304. Bouwens L, Houbracken I, Mfopou JK. The use of stem cells
for pancreatic regeneration in diabetes mellitus. Nat Rev
Endocrinol. Oct 2013;9(10):[598]e606.
